WO1996009379A1 - Dna purification and isolation using a solid phase - Google Patents

Dna purification and isolation using a solid phase Download PDF

Info

Publication number
WO1996009379A1
WO1996009379A1 PCT/US1995/011839 US9511839W WO9609379A1 WO 1996009379 A1 WO1996009379 A1 WO 1996009379A1 US 9511839 W US9511839 W US 9511839W WO 9609379 A1 WO9609379 A1 WO 9609379A1
Authority
WO
WIPO (PCT)
Prior art keywords
dna
magnetic microparticles
concentration
solution
microparticles
Prior art date
Application number
PCT/US1995/011839
Other languages
French (fr)
Inventor
Trevor Hawkins
Original Assignee
Whitehead Institute For Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute For Biomedical Research filed Critical Whitehead Institute For Biomedical Research
Publication of WO1996009379A1 publication Critical patent/WO1996009379A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/1013Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by using magnetic beads
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Definitions

  • the present invention is a method of binding polynucieotides non-specifically and reversibly to a solid phase which reversibly binds polynucieotides, such as magnetic microparticles whose surfaces are coated with a functional group, such as a carboxyl group.
  • the polynucieotides can be DNA, RNA or polyamide nucleic acids (PNAs) .
  • the method comprises combining the solid phase, such as magnetic microparticles and a solution containing polynucieotides.
  • the salt concentration and polyalkylene glycol concentration of the resulting combination are adjusted to concentrations suitable for binding polynucieotides to the surface of the solid phase, such as to surfaces of the magnetic microparticles; as a result, polynucieotides are bound non-specifically to the magnetic microparticles.
  • the present invention also relates to a method of separating polynucieotides, such as DNA, RNA and PNA, from a solution containing polynucieotides.
  • the method comprises binding polynucieotides non-specifically to a solid surface, such as to magnetic microparticles, as described above, washing the resulting bound polynucieotides with a high ionic strength buffer, and eluting the polynucieotides with a low ionic strength elution buffer.
  • the method described herein is useful to separate double stranded (ds) or single stranded (ss) polynucieotides (e.g., DNA, RNA, PNA) of virtually any size and from a wide variety of sources.
  • the present method can be used to separate DNA present in a transfected host cell, DNA resulting from an amplification process (e.g., polymerase chain reaction, PCR) and DNA in gels, such as agarose gels.
  • amplification process e.g., polymerase chain reaction, PCR
  • DNA in gels such as agarose gels.
  • biochemical reactions and sequencing can be performed on DNA bound to the magnetic microparticles.
  • the present invention also relates to a kit comprising magnetic microparticles and a binding buffer which contains a suitable salt and polyalkylene glycol at concentrations suitable for reversibly binding polynucleotide onto solid surfaces, such as to the surfaces of magnetic microparticles.
  • the kit may additionally comprise a suitable wash buffer, elution buffer, reagents for preparing such buffers or reagents for preparing a cleared lysate.
  • the method of the present invention is useful with both single and double stranded polynucieotides, as well as a wide range of polynucleotide fragment sizes, it has applicability in essentially any context in which polynucleotide separation is desired. In addition, this permits the standardization of manipulations and isolation carried out with polynucieotides.
  • the present method simplifies the isolation of cloned DNA from lysate by obviating the need for centrifugation and produces a plasmid ready for sequencing and further characterization and processing.
  • the present method also has the advantage that is fast, thus allowing for the rapid throughput in isolating polynucleotides, low cost and simple to perform and produces high yields of polynucieotides.
  • polynucieotides bind reversibly and non-specifically to solid surfaces, such as certain magnetic microparticles, at certain concentrations of salt and polyalkylene glycol.
  • a method for convenient and rapid separation of polynucieotides, such as DNA, RNA and PNA, from other biomolecules, such as proteins, monosaccharides, polysaccharides, lipids and RNA and from cellular components, such as cell membranes is available.
  • a method for separation of polynucieotides on the basis of size. The following is a description of the present invention with reference to polynucieotides as exemplified by DNA.
  • One embodiment of the present invention is a method of separating DNA from a solution containing DNA. The method comprises a first step of reversibly binding DNA non-specifically to a solid surface, such as magnetic microparticles whose surfaces are coated with functional groups.
  • the magnetic microparticles are combined with a solution of DNA, after which the salt concentration and the polyethylene glycol concentration of the resulting combination are adjusted to a concentration suitable for binding DNA onto the surface of the magnetic particles.
  • sufficient salt and polyethylene glycol are added to the solution containing magnetic microparticle-bound DNA to result in a final concentration of from about .5 M to about 5.0 M salt and from about 7% to about 13% polyethylene glycol.
  • DNA is bound non-specifically to the surfaces of the magnetic microparticles.
  • the magnetic microparticles in the resulting combination are separated from the supernatant.
  • the magnetic microparticles having DNA bound thereto can, optionally, be washed with a suitable wash buffer before they are contacted with a suitable elution buffer, to elute and separate the DNA from the magnetic microparticles.
  • the magnetic particles are separated from the elution buffer, which contains the polynucleotide, in solution.
  • the magnetic microparticles are separated from the elution buffer by, for example, filtration or applying a magnetic field to draw down the microparticles.
  • Magnetic microparticles are microparticles which are attracted by a magnetic field.
  • the magnetic microparticles used in the method of the present invention comprise a magnetic metal oxide core, which is generally surrounded by an adsorptively or covalently bound silane coat to which a wide variety of bioaffinity adsorbents can be covalently bound through selected coupling chemistries, thereby coating the surface of the microparticles with functional groups.
  • the magnetic metal oxide core is preferably iron oxide, wherein iron is a mixture of Fe 2* and Fe 3* .
  • the preferred Fe 2* /Fe 3* ratio is preferably 2/1, but can vary from about 0.5/1 to about 4/1.
  • Suitable amino silanes useful to coat the microparticle surfaces include p- aminopropyltrimethoxysilane, N-2-aminoethyl-3- aminopropyltrimethoxysilane, triaminofunctional silane (H 2 NCH 2 -NH-CH 2 CH 2 -NH-CH 2 -Si- (OCH 3 ) 3 , n-dodecyltriethoxysilane and n-hexyltrimethoxysilane.
  • the term "functional group-coated surface” refers to a surface which is coated with moieties which each have a free functional group which is bound to the amino group of the amino silane on the microparticle; as a result, the surfaces of the microparticles are coated with the functional group containing moieties.
  • the functional group acts as a bioaffinity absorbent for DNA in solution.
  • the functional group is a carboxylic acid.
  • a suitable moiety with a free carboxylic acid functional group is a succinic acid moiety in which one of the carboxylic acid groups is bonded to the amine of amino silanes through an amide bond and the second carboxylic acid is unbonded, resulting in a free carboxylic acid group attached or tethered to the surface of the magnetic microparticle.
  • Carboxylic acid-coated magnetic microparticles are commercially available from PerSeptive Diagnostics (BioMag COOH, Catalog Number 8-4125) .
  • Suitable functional groups which can used for coating the surface of the magnetic microparticles include, but are not limited to thiol groups (microparticles with thiol group coating are commercially available from PerSeptive Diagnostics, Division of PerSeptive Biosystems, Catalog Number 8-4135) and streptavidin (microparticles with a streptavidin coating are commercially available from PerSeptive Diagnostics, Division of PerSeptive Biosystems, Catalog Number 8-4135) and streptavidin (microparticles with a streptavidin coating are commercially available from
  • Magnetic microparticles coated with thiol groups or streptavidin bind DNA less efficiently than carboxyl group-coated microparticles.
  • the importance of having functional groups coat the surface of microparticles used is demonstrated by the observation that polymer encapsulated magnetic microparticles do not bind DNA in the method of the present invention.
  • Polymer encapsulated microparticles are commercially available from Dynal, Incorporated, Dynabeads M-280, (Catalog Number 112.06) .
  • Magnetic microparticles useful in the present method can be a variety of shapes, which can be regular or irregular; preferably the shape maximizes the surface areas of the microparticles.
  • the magnetic microparticles should be of such a size that their separation from solution, for example by filtration or magnetic separation, is not difficult.
  • the magnetic microparticles should not be so large that surface area is minimized or that they are not suitable for microscale operations. Suitable sizes range from about 0.1 ⁇ mean diameter to about 100 ⁇ mean diameter. A preferred size is about 1.0 ⁇ mean diameter. Suitable magnetic microparticles are commercially available from PerSeptive Diagnostics and are referred to as BioMag COOH (Catalog Number 8-4125) .
  • Non-specific DNA binding refers to binding of different DNA molecules with approximately the same affinity to magnetic microparticles, despite differences in the DNA sequence or size of the different DNA molecules.
  • a polynucleotide can be DNA, RNA or a synthetic DNA analog such as a PNA (Nielsen et al . , Science, 254:1497 (1991)) .
  • Non-specific DNA binding refers to binding of different DNA molecules with approximately the same affinity to magnetic microparticles despite differences in the nucleic acid sequence or size of the different DNA molecules.
  • a solution containing DNAs can be any aqueous solution, such as a solution containing DNA, RNA and/or PNAs.
  • Such a solution can also contain other components, such as other biomolecules, inorganic compounds and organic compounds.
  • the solution can contain DNA which is the reaction product of PCR amplification.
  • the solution can also be a cleared lysate.
  • a "lysate”, as used herein, is a solution containing cells which contain cloned DNA and genomic DNA and whose cell membranes have been disrupted, with the result that the contents of the cell, including the DNA contained therein, are in the solution.
  • a “cleared lysate” is a lysate in which the chromosomal DNA, proteins and membranes of the host cells have been selectively removed, such as by chemical treatment or centrifugation of the lysate, thereby leaving a solution containing plasmid DNA.
  • RNase can be added to create a "cleared lysate" free of RNA, thereby allowing DNA to bind to the magnetic microparticles free from RNA.
  • Methods of creating a cleared lysate are well-known in the art. For example, a cleared lysate can be produced by treating the host cells with sodium hydroxide or its equivalent (0.2 N) and sodium dodecyl sulfate (SDS) (1%) . This method of creating a cleared lysate is described in detail in Birnboim and Doly, Nucl . Acids Res .
  • a host cell is any cell, such as a bacterial cell such as E. coli , a mammalian cell or a yeast cell which contains exogenous or foreign D ⁇ A, in addition to genomic D ⁇ A.
  • the foreign D ⁇ A may be introduced directly into the host cell by means known to one of ordinary skill in the art .
  • Examples of foreign D ⁇ A introduced directly into a host cell include bacterial artificial chromosomes (BAC) , yeast artificial chromosomes (YAC) , plasmids, cosmids and PI.
  • BACs are particularly difficult to separate and purify from cleared lysates due to their low concentrations in the lysates. (Shizuya et al . ) However, BACs are readily separated by the method of the present invention.
  • the plasmid D ⁇ A may be introduced into the host cell by a phage into which the plasmid D ⁇ A has been packaged. Suitable plasmid D ⁇ As which can be packaged into a phage include a cosmid or PI . Host cells containing foreign D ⁇ A introduced by any method are referred to as transfected host cells.
  • the solution with which the magnetic microparticles is combined may also contain single stranded polynucieotides.
  • the present invention is useful to separate polynucieotides from a solution which is the supernatant from a recombinant D ⁇ A-containing M13 bacteriophage isolate which had been used to infect bacterial host cells.
  • the host cells are removed from the supernatant by filtration (Kristensen, et al . , Nucl . Acids Res . , 15:550-16 (1987)) or by binding the host cells to amine coated surfaces (Hou and
  • Single stranded D ⁇ A is released from the M13 bacteriophage into the solution by adding SDS to a final concentration of about 0.3% to about 3%, preferably about 1% and at a temperature from about 60°C to about 100°C, preferably 80°C.
  • the DNA-containing solution may also be an agarose solution.
  • a mixture of DNA is separated, according to methods known to one skilled in the art, such as by electrophoresis on an agarose gel.
  • a plug of agarose containing DNA of interest can be excised from the gel and added to 1-10 volumes of 0.5 x SSC ( .75 M NaCI, .0075 M Sodium Citrate, pH 7.0) preferably 4 volumes.
  • the mixture is then melted at a temperature of from about 60°C to about 100°C, preferably at about 80°C for about one to about twenty minutes, preferably ten minutes, to create an agarose solution containing DNA.
  • the second step of the present method of binding DNA non-specifically to magnetic microparticles having a functional group-coated surface comprises adjusting the salt concentration and the polyalkylene glycol concentration of the combination to a concentration of each suitable for binding DNA reversibly onto the surface of the magnetic particles.
  • Suitable polyalkylene glycols include polyethylene glycol (PEG) and polypropylene glycol.
  • PEG poly(ethylene glycol)
  • a sufficient quantity of a salt and a sufficient quantity of PEG are combined with the combination of magnetic microparticles and DNA-containing solution to produce a final salt concentration of from about 0.5 M to about 5.0 M and a final PEG concentration of from about 7% to about 13%.
  • DNA binds non-specifically to the surface of the magnetic microparticles. The binding of the DNA to the magnetic microparticles is rapid; it is generally complete within thirty seconds.
  • Salts which have been found to be suitable for binding DNA to the microparticles include sodium chloride (NaCI) , lithium chloride (LiCl) , barium chloride (BaCl 2 ) , potassium (KC1) , calcium chloride (CaCl 2 ) , magnesium chloride (MgCl 2 ) and cesium chloride (CeCl) .
  • sodium chloride is used.
  • the wide range of salts suitable for use in the method indicates that many other salts can also be used and can be readily determined by one of ordinary skill in the art. Yields of bound DNA decrease if the salt concentration is adjusted to less than about 0.5 M or greater than about 5.0 M. The salt concentration is preferably adjusted to about 1.25 M.
  • the molecular weight of the polyethylene glycol (PEG) can range from about 6000 to about 10,000, with a molecular weight of about 8000 being preferred.
  • the concentration of PEG is preferably adjusted to about 10%. Although concentrations of PEG as low as 7% and as high as 13% can be used, yields of bound DNA drop as the concentration of PEG deviates from 10%.
  • the method of the present invention is useful to separate DNA from a solution containing polynucleotide. As discussed above, the method comprises binding DNA nonspecifically and reversibly to magnetic microparticles having a functional group coated (e.g., carboxyl-coated) surface.
  • the microparticles are then separated from the supernatant, for example by applying a magnetic field to draw down the magnetic microparticles.
  • the remaining solution i.e. supernatant
  • the DNA can be removed from the magnetic microparticles particles by washing with a suitable elution buffer.
  • An elution buffer is any aqueous solution in which the salt concentration and polyalkylene concentration are below the ranges required for binding of DNA onto magnetic microparticles, as discussed above.
  • sucrose (20%) and formamide (100%) solutions can be used to elute the DNA.
  • a preferred eluent is water. Elution of the DNA from the microparticles occurs in thirty seconds or less when an elution buffer of low ionic strength, for example water, is used. Once the bound DNA has been eluted, the magnetic microparticles are separated from the elution buffer that contains the eluted DNA. Preferably, the magnetic microparticles are separated from the elution buffer by magnetic means, as described above. Other methods known to those skilled in the art can be used to separate the magnetic microparticles from the supernatant; for example, filtration can be used. Yields of DNA following elution typically approach 100% when the magnetic microparticles are used in excess.
  • the magnetic microparticles with bound DNA are washed with a suitable wash buffer solution before separating the DNA from the microparticles by washing with an elution buffer.
  • a suitable wash buffer solution has several characteristics. First, the wash buffer solution must have a sufficiently high salt concentration (i.e., has a sufficiently high ionic strength) that the DNA bound to the magnetic microparticles does not elute off of the microparticles, but remains bound to the microparticles. Suitable salt concentrations are greater than about 1.0 M and is preferably about 5.0 M. Second, the buffer solution is chosen so that impurities that are bound to the DNA or microparticles are dissolved.
  • the pH and solute composition and concentration of the buffer solution can be varied according to the type of impurities which are expected to be present.
  • Suitable wash solutions include the following: 0.5 x 5 SSC ; 100 mM ammonium sulfate, 400 mM Tris pH 9, 25 mM MgCl 2 and 1% bovine serum albumine (BSA) ; and 5 M NaCI .
  • a preferred wash buffer solution comprises 25 mM Tris acetate (pH 7.8), 100 mM potassium acetate (KOAc) , 10 mM magnesium acetate (Mg 2 0Ac) , and 1 mM dithiothreital (DTT) .
  • the magnetic microparticles with bound DNA can also be washed with more than one wash buffer solution.
  • the magnetic microparticles can be washed as often as required to remove the desired impurities.
  • the number of washings is preferably limited to two or three in order to minimize loss of yield of the bound DNA. Yields of DNA when the microparticles are used in excess are typically about 80% after washing with a wash buffer and eluting with an elution buffer.
  • the polynucleotide in the solution with which the magnetic microparticles are combined can be single stranded or double stranded.
  • the polynucleotide can be homogeneous (i.e. polynucieotides which have the same nucleotide sequence) .
  • the polynucleotide can be heterogeneous, (i.e., polynucieotides of differing nucleotide sequences) .
  • the polynucleotide can also comprise a DNA library or partial library.
  • the DNA can also comprise molecules of various lengths.
  • DNA fragments of 23Kb, 9Kb, 64Kb, 4Kb, 2Kb and 12bp derived from the electrophoretic separation of a HINDIII cut lambda marker were cut out of the agarose gel and purified by the method of the present invention (see Example 7) .
  • Temperature does not appear to be critical in the method of separating DNA of the present invention. Ambient temperature is preferred, but any temperature above the freezing point of water and below the boiling point of water can be used.
  • DNA fragments of all sizes bind non-specifically to magnetic microparticles at high ionic strength. High ionic strength refers to salt concentrations greater than 0.5 M. However, smaller fragments of DNA bind with lower affinity than large DNA fragments at lower ionic strengths, for example, about 0.5 M salt concentration and lower.
  • Another embodiment of the present invention refers to a method of separating a mixture of polynucleotide fragments, such as DNA fragments, based on size. For example, a solution of DNA fragments of different sizes is first combined with magnetic microparticles having a carboxyl group-coated surface under conditions appropriate for non ⁇ specific binding of DNA to the magnetic microparticles. The magnetic microparticles are then separated from the supernatant.
  • the polynucleotide bound to the magnetic microparticles can be washed with a suitable wash buffer which dissolves bound impurities, but is of high enough ionic strength that the polynucleotide remains attached to the magnetic microparticles.
  • the magnetic microparticles are then washed with an elution buffer of appropriate ionic strength to elute the smaller size polynucleotide fragments, but leave the larger size polynucleotide fragments bound to the magnetic microparticles.
  • the smaller polynucleotide fragments, such as DNA, in the elution buffer can then be isolated in the usual manner or processed further, e.g., subjected to further biochemical reactions. This method has been used to separate PCR primers from the reaction product of a PCR amplification (see Example 6) .
  • the polynucleotide (e.g., DNA) which remains bound to the magnetic particles can then be eluted with a suitable elution buffer.
  • the DNA can then be isolated in the usual manner, or processed further, e.g. subjected to further biochemical reactions.
  • the DNA which remains bound to the magnetic microparticles can be subjected to further size selection by washing with an elution buffer of sufficiently low ionic strength to elute the smaller remaining DNA fragment, but of sufficiently high enough ionic strength to allow the larger remaining polynucleotide fragments to remain bound to the magnetic microparticles.
  • the separation of polynucleotide fragments (e.g., DNA fragments) based on size can also be accomplished by the method of the present invention by adjusting the PEG concentration, the molecular weight of the PEG used or both.
  • One embodiment of the present invention is based on the discovery that the magnetic microparticles do not bind enzymes. The magnetic microparticles also do not inhibit the function of enzymes. It is therefore possible to carry out biochemical reactions on DNA bound to the magnetic microparticles, e.g., by exposing the bound DNA to enzymes capable of biochemically modifying the bound DNA under conditions which cause the biochemical modification to take place.
  • the biochemical reactions are carried out on purified bound DNA (e.g., DNA bound to microparticles which have been separated from a cleared lysate or from a solution in which a biochemical reaction such as PCR was carried out) .
  • the purified bound DNA can also be washed with a suitable wash buffer. Because residual salt can inhibit the activity of certain enzymes, it is preferable that washings with high ionic strength salt solutions be followed with a washing with a lower ionic strength solution. The ionic strength of this solution should be low enough that enough residual salt is removed to prevent enzyme inhibition, but not so low that substantial losses in bound DNA result.
  • the DNA bound to the magnetic microparticles is digested with a restriction enzyme.
  • the restriction enzyme-digested DNA can then be end-repaired, if necessary, for later ligation to a vector by suitable end- repair enzymes.
  • the end-repaired DNA is typically eluted by the solvent in which the biochemical reaction takes place.
  • the magnetic microparticles are washed with a suitable elution buffer to ensure complete separation of the end-repaired DNA from the microparticles.
  • the magnetic microparticles are then separated from the reaction mixture or elution buffer, preferably by magnetic separation.
  • the solution containing the end-repaired DNA can then be combined with a solution containing a pre-cut vector suitable for ligation to the eluted DNA.
  • the end-repaired DNA can then be ligated to the pre-cut vector by methods known to those skilled in the art. After ligation, the DNA can be transformed into a host cell in the usual way.
  • a DNA library is bound to the magnetic microparticles.
  • the DNA bound to the magnetic microparticles will consist of molecules of various sizes and nucleotide sequences (heterogeneous DNA) . Specific size fragments can be eluted from the magnetic microparticles by varying the ionic strength of the elution buffer, as described earlier. Alternatively, the concentration, molecular weight or both of the PEG in the elution buffer can be varied, as described earlier, to selectively elute smaller DNA fragments.
  • the DNA fragments which remain bound to the magnetic microparticles can be digested with one or more restriction enzymes and then ligated into a pre-cut vector, as described above. A vector is thereby created in which the DNA insert has a certain size. The vector can then be transformed into a host cell in the usual way.
  • the nucleotide sequence of the DNA bound to the magnetic microparticles is determined directly without an elution step which releases the DNA from the magnetic microparticles.
  • DNA is bound to the microparticles as described above.
  • the microparticles with bound DNA are then separated from the supernatant and combined with the reagents used for determining nucleotide sequences under conditions suitable for sequence determination. Suitable reagents and conditions are known to those skilled in the art (See Sanger et al . , Proc . Na t . Acad. Sci . , 74:5463 (1977) and the ABI 373 Sequencer Manual) .
  • a kit is also provided herein which contains the reagents necessary for separating polynucieotides, such as DNA, RNA and PNAs, from a solution containing polynucieotides by binding the polynucieotides to a solid surface, such as magnetic microparticles having a carboxyl group-coated surface.
  • the kit comprises magnetic microparticles with a carboxyl group-coated surface and a binding buffer.
  • the binding buffer comprises a suitable salt and a suitable polyalkylene glycol which are both present at a concentration suitable for binding DNA to the surface of the magnetic microparticles.
  • the kit further comprises an elution buffer which is capable of dissolving the polynucleotide, such as DNA, bound to the magnetic microparticles.
  • the kit can comprise the reagents for making the binding and/or elution buffer, to which a known amount of water can be added to create a binding and/or elution buffer of desired concentration.
  • the kit further comprises a wash buffer which dissolves impurities bound to the magnetic microparticles, but does not result in elution of the polynucleotide bound to the magnetic microparticles.
  • the kit can comprise the reagents for making the wash buffer, to which a known amount of water can be added to create a wash buffer of desired concentration.
  • the kit comprises the reagents necessary for clearing a cell lysate.
  • the reagents are present in solutions at a concentration suitable for direct use in preparing a cleared lysate without the need for further diluting the solutions.
  • the magnetic particles used in the following examples were the carboxyl coated magnetic microparticles from PerSeptive Diagnostics Massachusetts, (Biomag COOH, Catalog Number 8-4125) particles which were 1 ⁇ m in diameter.
  • the particles were stored in phosphate buffered saline (PBS) at a concentration of 20 mg/ml. All agarose gels were run using 1% final agarose (U.S. Biochemical #32827) with lx TBE buffers. The field strength was lOV/cm with run times from 40-60 minutes. The gels were post-stained with ethidium bromide and visualized under UV.
  • PBS phosphate buffered saline
  • a pUC plasmid (pUC 18, obtained from U.S. Biochemicals, Catalog Number 70070) was purified from its host cell by creating a cleared lysate, reversibly binding the plasmid to the magnetic microparticles, separating the magnetic microparticles and then eluting the DNA. The following procedure was used:
  • a pUC plasmid (pUC 18, obtained from U.S. Biochemicals Catalog Number 70070) grown in microtitre plates was purified from its host cell by creating a cleared lysate, reversibly binding the plasmid to the magnetic microparticles, separating the magnetic microparticles and then eluting the DNA. The following procedure was used:
  • This example yields 500-800ng plasmid DNA which is sufficient for thermal cycle DNA sequencing.
  • the advantage of using a microtitre plate is that many samples can be isolated in parallel.
  • electrophoretic analysis of the cleared lysate after binding to the magnetic microparticles showed no DNA, while electrophoretic analysis of the eluent from microparticles showed purified pUC plasmid.
  • Example 3 Isolating Large DNA Vectors From 500 ml Cultures A cosmid (pWE15, obtained from Stratagene, Catalog Number 251201) containing a 35Kb insert and a Bacterial Artificial Chromosome were purified from their host cells by creating a cleared lysate, binding the DNA to the magnetic microparticles, separating the magnetic microparticles from the cleared lysate, and then eluting the DNA. The following procedure was used:
  • Electrophoretic analysis of the solutions obtained from washing the magnetic microparticles with water showed purified cosmid cloned containing the 35Kb insert and the 150Kb BAC (Bacterial Artificial Chromosome) clone which had been cut with Notl to excise the 7Kb vector.
  • Example 4 Single Stranded DNA Isolation from Bacteriophages Using the PEG Induced Precipitate Separation Single stranded DNA from M13 clones using E. coli (DH5 ⁇ F' culture, obtained from U.S. Biochemicals Catalog Number 75112) as a host was isolated by lysing the phage, binding the single stranded DNA to the magnetic microparticles, from separating the magnetic microparticles the supernatant and then eluting the DNA. The following procedure was used:
  • Electrophoretic analysis of the solution obtained from washing the magnetic microparticles with water showed purified M13 single stranded DNA.
  • Example 5 DNA Sequence from a Plasmid Clone Isolated Using the PEG Induced Precipitate Separation. DNA which had been isolated using the procedure described in example 1 was then sequenced using Taq poly erase and fluorescently labelled primers. The DNA sequence was then electrophoresed on an ABI 373A DNA sequence. The clarity of the data, the read length and the lack of ambiguous bases indicated DNA of high purity.
  • DNA isolations may also be performed from amplified DNA such as PCR products.
  • PCR product purification is the removal of residual nucleotides, oil and excess primers (18-25bp DNA fragments) , which may interfere with subsequent reactions.
  • This example demonstrates the isolation of PCR products as well as the selective removal of the primers during the wash stages.
  • Bind the DNA products Take 10 ⁇ l (@20 mg/ml) carboxyl coated magnetic particles, wash three times in 0.5 M EDTA pH 7.2 and resuspend in 10 ⁇ l 0.5 M EDTA. Add to the PCR amplifiers.
  • Electrophoretic analysis of the PCR reaction mixture before binding to the magnetic microparticles showed the presence of primers as well as the final product. Electrophoretic analysis after elution from the magnetic microparticles show that the primers were removed from the amplification product.
  • DNA fragments were isolated directly from molten agarose plugs.
  • a Lambda marker was cut with HINDIII and electrophoresed. Bands corresponding to 23Kb, 9Kb, 6Kb, 4Kb, and 2Kb and 125bp bands were excised and isolated from the molten agarose according to the following procedure.

Abstract

A method of separating polynucleotides, such as DNA, RNA and PNA, from a solution containing polynucleotides by reversibly and non-specifically binding the polynucleotides to a solid surface, such as a magnetic microparticle, having a functional group-coated surface is disclosed. The salt and polyalkylene glycol concentration of the solution is adjusted to levels which result in polynucleotide binding to the magnetic microparticles. The magnetic microparticles with bound polynucleotides are separated from the solution and the polynucleotides are eluted from the magnetic microparticles.

Description

DNA PURIFICATION AND ISOLATION USING A SOLID PHASE
Background of the Invention
Preparation and manipulation of high quality DNA is a vital step in molecular biology. Although there are many methods reported for single and double stranded DNA isolations (Bankier, A. et al . , Meth . Enz . , 155:52-93 (1988); Birnboim, H. et al . , Nucl . Acids Res . , 7:1513 (1979) ; Ish-Horowicz, D. et al . , Nucl . Acids Res . , 9 : 2989 (1981) ; Kristensen, T. et al . , Nucl . Acids Res . , 25:5507-5516 (1987) ; Smith, V. et al . , DNA Seq. and Mapping , 1:73-78 (1990)) , there are few procedures that are rapid, low cost and procedurally identical for all DNA types, from PCR product to single copy BAC clone.
Summary of the Invention The present invention is a method of binding polynucieotides non-specifically and reversibly to a solid phase which reversibly binds polynucieotides, such as magnetic microparticles whose surfaces are coated with a functional group, such as a carboxyl group. The polynucieotides can be DNA, RNA or polyamide nucleic acids (PNAs) . The method comprises combining the solid phase, such as magnetic microparticles and a solution containing polynucieotides. The salt concentration and polyalkylene glycol concentration of the resulting combination are adjusted to concentrations suitable for binding polynucieotides to the surface of the solid phase, such as to surfaces of the magnetic microparticles; as a result, polynucieotides are bound non-specifically to the magnetic microparticles. The present invention also relates to a method of separating polynucieotides, such as DNA, RNA and PNA, from a solution containing polynucieotides. The method comprises binding polynucieotides non-specifically to a solid surface, such as to magnetic microparticles, as described above, washing the resulting bound polynucieotides with a high ionic strength buffer, and eluting the polynucieotides with a low ionic strength elution buffer.
The method described herein is useful to separate double stranded (ds) or single stranded (ss) polynucieotides (e.g., DNA, RNA, PNA) of virtually any size and from a wide variety of sources. For example, the present method can be used to separate DNA present in a transfected host cell, DNA resulting from an amplification process (e.g., polymerase chain reaction, PCR) and DNA in gels, such as agarose gels. In addition, biochemical reactions and sequencing can be performed on DNA bound to the magnetic microparticles.
The present invention also relates to a kit comprising magnetic microparticles and a binding buffer which contains a suitable salt and polyalkylene glycol at concentrations suitable for reversibly binding polynucleotide onto solid surfaces, such as to the surfaces of magnetic microparticles. The kit may additionally comprise a suitable wash buffer, elution buffer, reagents for preparing such buffers or reagents for preparing a cleared lysate.
Because the method of the present invention is useful with both single and double stranded polynucieotides, as well as a wide range of polynucleotide fragment sizes, it has applicability in essentially any context in which polynucleotide separation is desired. In addition, this permits the standardization of manipulations and isolation carried out with polynucieotides. The present method simplifies the isolation of cloned DNA from lysate by obviating the need for centrifugation and produces a plasmid ready for sequencing and further characterization and processing. The present method also has the advantage that is fast, thus allowing for the rapid throughput in isolating polynucleotides, low cost and simple to perform and produces high yields of polynucieotides. These properties, coupled with its applicability to many procedures useful in molecular biology, make the method amenable to automation.
Detailed Description of the Invention
As described herein, Applicant has shown that polynucieotides bind reversibly and non-specifically to solid surfaces, such as certain magnetic microparticles, at certain concentrations of salt and polyalkylene glycol. As a result, a method for convenient and rapid separation of polynucieotides, such as DNA, RNA and PNA, from other biomolecules, such as proteins, monosaccharides, polysaccharides, lipids and RNA and from cellular components, such as cell membranes, is available. Also available is a method for separation of polynucieotides on the basis of size. The following is a description of the present invention with reference to polynucieotides as exemplified by DNA. It is to be understood that the present invention is also useful for separation of RNA and PNAs in a similar manner. Because small polynucieotides require higher salt concentrations for strong binding to the microparticles, salt concentrations can be selectively manipulated to release polynucieotides bound to magnetic microparticles on the basis of size. One embodiment of the present invention is a method of separating DNA from a solution containing DNA. The method comprises a first step of reversibly binding DNA non-specifically to a solid surface, such as magnetic microparticles whose surfaces are coated with functional groups. In the method, the magnetic microparticles are combined with a solution of DNA, after which the salt concentration and the polyethylene glycol concentration of the resulting combination are adjusted to a concentration suitable for binding DNA onto the surface of the magnetic particles. In one embodiment, sufficient salt and polyethylene glycol are added to the solution containing magnetic microparticle-bound DNA to result in a final concentration of from about .5 M to about 5.0 M salt and from about 7% to about 13% polyethylene glycol. As a result, DNA is bound non-specifically to the surfaces of the magnetic microparticles. Subsequently, the magnetic microparticles in the resulting combination are separated from the supernatant. The magnetic microparticles having DNA bound thereto can, optionally, be washed with a suitable wash buffer before they are contacted with a suitable elution buffer, to elute and separate the DNA from the magnetic microparticles. In a final step, the magnetic particles are separated from the elution buffer, which contains the polynucleotide, in solution. The magnetic microparticles are separated from the elution buffer by, for example, filtration or applying a magnetic field to draw down the microparticles.
Solid surfaces which bind DNA and have sufficient surface area to permit efficient binding can be used in the present invention. Microparticles, fibers, beads and supports contain suitable surfaces. Generally, magnetic microparticles are used in the present invention. As used herein, "magnetic microparticles" are microparticles which are attracted by a magnetic field. The magnetic microparticles used in the method of the present invention comprise a magnetic metal oxide core, which is generally surrounded by an adsorptively or covalently bound silane coat to which a wide variety of bioaffinity adsorbents can be covalently bound through selected coupling chemistries, thereby coating the surface of the microparticles with functional groups. The magnetic metal oxide core is preferably iron oxide, wherein iron is a mixture of Fe2* and Fe3* . The preferred Fe2*/Fe3* ratio is preferably 2/1, but can vary from about 0.5/1 to about 4/1. Suitable amino silanes useful to coat the microparticle surfaces include p- aminopropyltrimethoxysilane, N-2-aminoethyl-3- aminopropyltrimethoxysilane, triaminofunctional silane (H2NCH2-NH-CH2CH2-NH-CH2-Si- (OCH3)3, n-dodecyltriethoxysilane and n-hexyltrimethoxysilane. Methods of preparing these microparticles are described in U.S. Patent Nos. 4,628,037, 4,554,088, 4,672,040, 4,695,393 and 4,698,302, the teachings of which are hereby incorporated by reference into this application in their entirety. These patents disclose other amino silanes which are suitable to coat the iron oxide core and which are encompassed by this invention. Magnetic microparticles comprising an iron oxide core, as described above, without a silane coat (BioMag Iron Oxide particles available from PerSeptive Diagnostics, Division of PerSeptive Biosystems, Catalog Number 8-4200) can also be used in the method of the present invention.
As used herein, the term "functional group-coated surface" refers to a surface which is coated with moieties which each have a free functional group which is bound to the amino group of the amino silane on the microparticle; as a result, the surfaces of the microparticles are coated with the functional group containing moieties. The functional group acts as a bioaffinity absorbent for DNA in solution. In one embodiment, the functional group is a carboxylic acid. A suitable moiety with a free carboxylic acid functional group is a succinic acid moiety in which one of the carboxylic acid groups is bonded to the amine of amino silanes through an amide bond and the second carboxylic acid is unbonded, resulting in a free carboxylic acid group attached or tethered to the surface of the magnetic microparticle. Carboxylic acid-coated magnetic microparticles are commercially available from PerSeptive Diagnostics (BioMag COOH, Catalog Number 8-4125) . Other suitable functional groups which can used for coating the surface of the magnetic microparticles include, but are not limited to thiol groups (microparticles with thiol group coating are commercially available from PerSeptive Diagnostics, Division of PerSeptive Biosystems, Catalog Number 8-4135) and streptavidin (microparticles with a streptavidin coating are commercially available from
PerSeptive Diagnostics, BioMag Steptavidin, Catalog Number 8-MB4804) . As used herein, magnetic microparticles coated with thiol groups or streptavidin bind DNA less efficiently than carboxyl group-coated microparticles. The importance of having functional groups coat the surface of microparticles used is demonstrated by the observation that polymer encapsulated magnetic microparticles do not bind DNA in the method of the present invention. Polymer encapsulated microparticles are commercially available from Dynal, Incorporated, Dynabeads M-280, (Catalog Number 112.06) . The advantage of having a metal oxide core is illustrated by the observation that washing the magnetic microparticles with EDTA, which removes some of the iron, reduces the ability of the magnetic microparticles to bind DNA. Microparticles with a cellulose/iron oxide core, which are commercially available from Amersham International (Catalog Number NIF 876) did not bind DNA in the method of the present invention as it is described herein. Magnetic microparticles useful in the present method can be a variety of shapes, which can be regular or irregular; preferably the shape maximizes the surface areas of the microparticles. The magnetic microparticles should be of such a size that their separation from solution, for example by filtration or magnetic separation, is not difficult. In addition, the magnetic microparticles should not be so large that surface area is minimized or that they are not suitable for microscale operations. Suitable sizes range from about 0.1 μ mean diameter to about 100 μ mean diameter. A preferred size is about 1.0 μ mean diameter. Suitable magnetic microparticles are commercially available from PerSeptive Diagnostics and are referred to as BioMag COOH (Catalog Number 8-4125) .
"Non-specific DNA binding" refers to binding of different DNA molecules with approximately the same affinity to magnetic microparticles, despite differences in the DNA sequence or size of the different DNA molecules. A polynucleotide can be DNA, RNA or a synthetic DNA analog such as a PNA (Nielsen et al . , Science, 254:1497 (1991)) . "Non-specific DNA binding" refers to binding of different DNA molecules with approximately the same affinity to magnetic microparticles despite differences in the nucleic acid sequence or size of the different DNA molecules. "A solution containing DNAs" can be any aqueous solution, such as a solution containing DNA, RNA and/or PNAs. Such a solution can also contain other components, such as other biomolecules, inorganic compounds and organic compounds. The solution can contain DNA which is the reaction product of PCR amplification. The solution can also be a cleared lysate. A "lysate", as used herein, is a solution containing cells which contain cloned DNA and genomic DNA and whose cell membranes have been disrupted, with the result that the contents of the cell, including the DNA contained therein, are in the solution. A "cleared lysate" is a lysate in which the chromosomal DNA, proteins and membranes of the host cells have been selectively removed, such as by chemical treatment or centrifugation of the lysate, thereby leaving a solution containing plasmid DNA. RNase can be added to create a "cleared lysate" free of RNA, thereby allowing DNA to bind to the magnetic microparticles free from RNA. Methods of creating a cleared lysate are well-known in the art. For example, a cleared lysate can be produced by treating the host cells with sodium hydroxide or its equivalent (0.2 N) and sodium dodecyl sulfate (SDS) (1%) . This method of creating a cleared lysate is described in detail in Birnboim and Doly, Nucl . Acids Res . , 7:1513 (1979) Horowicz and Burke, Nucleic Acids Research 9:2989 (1981) , the teachings of which are hereby incorporated in their entirety into this reference. A host cell is any cell, such as a bacterial cell such as E. coli , a mammalian cell or a yeast cell which contains exogenous or foreign DΝA, in addition to genomic DΝA. The foreign DΝA may be introduced directly into the host cell by means known to one of ordinary skill in the art . Examples of foreign DΝA introduced directly into a host cell include bacterial artificial chromosomes (BAC) , yeast artificial chromosomes (YAC) , plasmids, cosmids and PI. BACs are particularly difficult to separate and purify from cleared lysates due to their low concentrations in the lysates. (Shizuya et al . ) However, BACs are readily separated by the method of the present invention. Alternatively, the plasmid DΝA may be introduced into the host cell by a phage into which the plasmid DΝA has been packaged. Suitable plasmid DΝAs which can be packaged into a phage include a cosmid or PI . Host cells containing foreign DΝA introduced by any method are referred to as transfected host cells.
The solution with which the magnetic microparticles is combined may also contain single stranded polynucieotides. For example, the present invention is useful to separate polynucieotides from a solution which is the supernatant from a recombinant DΝA-containing M13 bacteriophage isolate which had been used to infect bacterial host cells. The host cells are removed from the supernatant by filtration (Kristensen, et al . , Nucl . Acids Res . , 15:550-16 (1987)) or by binding the host cells to amine coated surfaces (Hou and
Zaniewski, Bioche , 12:315 (1990)) . Single stranded DΝA is released from the M13 bacteriophage into the solution by adding SDS to a final concentration of about 0.3% to about 3%, preferably about 1% and at a temperature from about 60°C to about 100°C, preferably 80°C. The DNA-containing solution may also be an agarose solution. For example, a mixture of DNA is separated, according to methods known to one skilled in the art, such as by electrophoresis on an agarose gel. A plug of agarose containing DNA of interest can be excised from the gel and added to 1-10 volumes of 0.5 x SSC ( .75 M NaCI, .0075 M Sodium Citrate, pH 7.0) preferably 4 volumes. The mixture is then melted at a temperature of from about 60°C to about 100°C, preferably at about 80°C for about one to about twenty minutes, preferably ten minutes, to create an agarose solution containing DNA.
As described above, the second step of the present method of binding DNA non-specifically to magnetic microparticles having a functional group-coated surface (e.g., a carboxyl-group-coated surface) comprises adjusting the salt concentration and the polyalkylene glycol concentration of the combination to a concentration of each suitable for binding DNA reversibly onto the surface of the magnetic particles. Suitable polyalkylene glycols include polyethylene glycol (PEG) and polypropylene glycol.
Generally, PEG is used. A sufficient quantity of a salt and a sufficient quantity of PEG are combined with the combination of magnetic microparticles and DNA-containing solution to produce a final salt concentration of from about 0.5 M to about 5.0 M and a final PEG concentration of from about 7% to about 13%. At appropriate concentrations of the two, DNA binds non-specifically to the surface of the magnetic microparticles. The binding of the DNA to the magnetic microparticles is rapid; it is generally complete within thirty seconds.
Salts which have been found to be suitable for binding DNA to the microparticles include sodium chloride (NaCI) , lithium chloride (LiCl) , barium chloride (BaCl2) , potassium (KC1) , calcium chloride (CaCl2) , magnesium chloride (MgCl2) and cesium chloride (CeCl) . In one embodiment sodium chloride is used. The wide range of salts suitable for use in the method indicates that many other salts can also be used and can be readily determined by one of ordinary skill in the art. Yields of bound DNA decrease if the salt concentration is adjusted to less than about 0.5 M or greater than about 5.0 M. The salt concentration is preferably adjusted to about 1.25 M.
The molecular weight of the polyethylene glycol (PEG) can range from about 6000 to about 10,000, with a molecular weight of about 8000 being preferred. The concentration of PEG is preferably adjusted to about 10%. Although concentrations of PEG as low as 7% and as high as 13% can be used, yields of bound DNA drop as the concentration of PEG deviates from 10%. The method of the present invention is useful to separate DNA from a solution containing polynucleotide. As discussed above, the method comprises binding DNA nonspecifically and reversibly to magnetic microparticles having a functional group coated (e.g., carboxyl-coated) surface. The microparticles are then separated from the supernatant, for example by applying a magnetic field to draw down the magnetic microparticles. The remaining solution, i.e. supernatant, can then be removed, leaving the microparticles with the bound DNA. Once separated from the supernatant, the DNA can be removed from the magnetic microparticles particles by washing with a suitable elution buffer. As a result, an elution buffer containing unbound DNA and magnetic microparticles is produced. An elution buffer is any aqueous solution in which the salt concentration and polyalkylene concentration are below the ranges required for binding of DNA onto magnetic microparticles, as discussed above. In addition, sucrose (20%) and formamide (100%) solutions can be used to elute the DNA. A preferred eluent is water. Elution of the DNA from the microparticles occurs in thirty seconds or less when an elution buffer of low ionic strength, for example water, is used. Once the bound DNA has been eluted, the magnetic microparticles are separated from the elution buffer that contains the eluted DNA. Preferably, the magnetic microparticles are separated from the elution buffer by magnetic means, as described above. Other methods known to those skilled in the art can be used to separate the magnetic microparticles from the supernatant; for example, filtration can be used. Yields of DNA following elution typically approach 100% when the magnetic microparticles are used in excess. In one embodiment, the magnetic microparticles with bound DNA are washed with a suitable wash buffer solution before separating the DNA from the microparticles by washing with an elution buffer. A suitable wash buffer solution has several characteristics. First, the wash buffer solution must have a sufficiently high salt concentration (i.e., has a sufficiently high ionic strength) that the DNA bound to the magnetic microparticles does not elute off of the microparticles, but remains bound to the microparticles. Suitable salt concentrations are greater than about 1.0 M and is preferably about 5.0 M. Second, the buffer solution is chosen so that impurities that are bound to the DNA or microparticles are dissolved. The pH and solute composition and concentration of the buffer solution can be varied according to the type of impurities which are expected to be present. Suitable wash solutions include the following: 0.5 x 5 SSC ; 100 mM ammonium sulfate, 400 mM Tris pH 9, 25 mM MgCl2 and 1% bovine serum albumine (BSA) ; and 5 M NaCI . A preferred wash buffer solution comprises 25 mM Tris acetate (pH 7.8), 100 mM potassium acetate (KOAc) , 10 mM magnesium acetate (Mg20Ac) , and 1 mM dithiothreital (DTT) . The magnetic microparticles with bound DNA can also be washed with more than one wash buffer solution. The magnetic microparticles can be washed as often as required to remove the desired impurities. However, the number of washings is preferably limited to two or three in order to minimize loss of yield of the bound DNA. Yields of DNA when the microparticles are used in excess are typically about 80% after washing with a wash buffer and eluting with an elution buffer.
The polynucleotide in the solution with which the magnetic microparticles are combined can be single stranded or double stranded. In addition, the polynucleotide can be homogeneous (i.e. polynucieotides which have the same nucleotide sequence) . Alternatively, the polynucleotide can be heterogeneous, (i.e., polynucieotides of differing nucleotide sequences) . The polynucleotide can also comprise a DNA library or partial library. The DNA can also comprise molecules of various lengths. For example, DNA fragments of 23Kb, 9Kb, 64Kb, 4Kb, 2Kb and 12bp derived from the electrophoretic separation of a HINDIII cut lambda marker were cut out of the agarose gel and purified by the method of the present invention (see Example 7) . Temperature does not appear to be critical in the method of separating DNA of the present invention. Ambient temperature is preferred, but any temperature above the freezing point of water and below the boiling point of water can be used. DNA fragments of all sizes bind non-specifically to magnetic microparticles at high ionic strength. High ionic strength refers to salt concentrations greater than 0.5 M. However, smaller fragments of DNA bind with lower affinity than large DNA fragments at lower ionic strengths, for example, about 0.5 M salt concentration and lower.
Another embodiment of the present invention refers to a method of separating a mixture of polynucleotide fragments, such as DNA fragments, based on size. For example, a solution of DNA fragments of different sizes is first combined with magnetic microparticles having a carboxyl group-coated surface under conditions appropriate for non¬ specific binding of DNA to the magnetic microparticles. The magnetic microparticles are then separated from the supernatant. Optionally, the polynucleotide bound to the magnetic microparticles can be washed with a suitable wash buffer which dissolves bound impurities, but is of high enough ionic strength that the polynucleotide remains attached to the magnetic microparticles. The magnetic microparticles are then washed with an elution buffer of appropriate ionic strength to elute the smaller size polynucleotide fragments, but leave the larger size polynucleotide fragments bound to the magnetic microparticles. The smaller polynucleotide fragments, such as DNA, in the elution buffer can then be isolated in the usual manner or processed further, e.g., subjected to further biochemical reactions. This method has been used to separate PCR primers from the reaction product of a PCR amplification (see Example 6) .
The polynucleotide (e.g., DNA) which remains bound to the magnetic particles can then be eluted with a suitable elution buffer. The DNA can then be isolated in the usual manner, or processed further, e.g. subjected to further biochemical reactions. Alternatively, the DNA which remains bound to the magnetic microparticles can be subjected to further size selection by washing with an elution buffer of sufficiently low ionic strength to elute the smaller remaining DNA fragment, but of sufficiently high enough ionic strength to allow the larger remaining polynucleotide fragments to remain bound to the magnetic microparticles. The separation of polynucleotide fragments (e.g., DNA fragments) based on size can also be accomplished by the method of the present invention by adjusting the PEG concentration, the molecular weight of the PEG used or both. One embodiment of the present invention is based on the discovery that the magnetic microparticles do not bind enzymes. The magnetic microparticles also do not inhibit the function of enzymes. It is therefore possible to carry out biochemical reactions on DNA bound to the magnetic microparticles, e.g., by exposing the bound DNA to enzymes capable of biochemically modifying the bound DNA under conditions which cause the biochemical modification to take place. Preferably the biochemical reactions are carried out on purified bound DNA (e.g., DNA bound to microparticles which have been separated from a cleared lysate or from a solution in which a biochemical reaction such as PCR was carried out) . The purified bound DNA can also be washed with a suitable wash buffer. Because residual salt can inhibit the activity of certain enzymes, it is preferable that washings with high ionic strength salt solutions be followed with a washing with a lower ionic strength solution. The ionic strength of this solution should be low enough that enough residual salt is removed to prevent enzyme inhibition, but not so low that substantial losses in bound DNA result. In one embodiment, the DNA bound to the magnetic microparticles is digested with a restriction enzyme. The restriction enzyme-digested DNA can then be end-repaired, if necessary, for later ligation to a vector by suitable end- repair enzymes. The end-repaired DNA is typically eluted by the solvent in which the biochemical reaction takes place. Alternatively, the magnetic microparticles are washed with a suitable elution buffer to ensure complete separation of the end-repaired DNA from the microparticles. The magnetic microparticles are then separated from the reaction mixture or elution buffer, preferably by magnetic separation. The solution containing the end-repaired DNA can then be combined with a solution containing a pre-cut vector suitable for ligation to the eluted DNA. The end-repaired DNA can then be ligated to the pre-cut vector by methods known to those skilled in the art. After ligation, the DNA can be transformed into a host cell in the usual way.
In another embodiment, a DNA library is bound to the magnetic microparticles. The DNA bound to the magnetic microparticles will consist of molecules of various sizes and nucleotide sequences (heterogeneous DNA) . Specific size fragments can be eluted from the magnetic microparticles by varying the ionic strength of the elution buffer, as described earlier. Alternatively, the concentration, molecular weight or both of the PEG in the elution buffer can be varied, as described earlier, to selectively elute smaller DNA fragments. The DNA fragments which remain bound to the magnetic microparticles can be digested with one or more restriction enzymes and then ligated into a pre-cut vector, as described above. A vector is thereby created in which the DNA insert has a certain size. The vector can then be transformed into a host cell in the usual way.
In another embodiment, the nucleotide sequence of the DNA bound to the magnetic microparticles is determined directly without an elution step which releases the DNA from the magnetic microparticles. DNA is bound to the microparticles as described above. The microparticles with bound DNA are then separated from the supernatant and combined with the reagents used for determining nucleotide sequences under conditions suitable for sequence determination. Suitable reagents and conditions are known to those skilled in the art (See Sanger et al . , Proc . Na t . Acad. Sci . , 74:5463 (1977) and the ABI 373 Sequencer Manual) . A kit is also provided herein which contains the reagents necessary for separating polynucieotides, such as DNA, RNA and PNAs, from a solution containing polynucieotides by binding the polynucieotides to a solid surface, such as magnetic microparticles having a carboxyl group-coated surface. The kit comprises magnetic microparticles with a carboxyl group-coated surface and a binding buffer. The binding buffer comprises a suitable salt and a suitable polyalkylene glycol which are both present at a concentration suitable for binding DNA to the surface of the magnetic microparticles. In one embodiment, the kit further comprises an elution buffer which is capable of dissolving the polynucleotide, such as DNA, bound to the magnetic microparticles. Alternatively, instead of a binding buffer and/or elution buffer, the kit can comprise the reagents for making the binding and/or elution buffer, to which a known amount of water can be added to create a binding and/or elution buffer of desired concentration.
In another embodiment, the kit further comprises a wash buffer which dissolves impurities bound to the magnetic microparticles, but does not result in elution of the polynucleotide bound to the magnetic microparticles. Alternatively, instead of a wash buffer, the kit can comprise the reagents for making the wash buffer, to which a known amount of water can be added to create a wash buffer of desired concentration.
In yet another embodiment, the kit comprises the reagents necessary for clearing a cell lysate. In a preferred embodiment, the reagents are present in solutions at a concentration suitable for direct use in preparing a cleared lysate without the need for further diluting the solutions.
The present invention will now be illustrated by the following examples, which are not limiting in any way.
General Methodolocrv The magnetic particles used in the following examples were the carboxyl coated magnetic microparticles from PerSeptive Diagnostics Massachusetts, (Biomag COOH, Catalog Number 8-4125) particles which were 1 μm in diameter. The particles were stored in phosphate buffered saline (PBS) at a concentration of 20 mg/ml. All agarose gels were run using 1% final agarose (U.S. Biochemical #32827) with lx TBE buffers. The field strength was lOV/cm with run times from 40-60 minutes. The gels were post-stained with ethidium bromide and visualized under UV.
Example 1 - Double Stranded DNA Isolation using the PEG Induced Precipitate Separation
A pUC plasmid (pUC 18, obtained from U.S. Biochemicals, Catalog Number 70070) was purified from its host cell by creating a cleared lysate, reversibly binding the plasmid to the magnetic microparticles, separating the magnetic microparticles and then eluting the DNA. The following procedure was used:
1. Take 1 ml of overnight culture containing the plasmid clone in an Eppeπdorf™ tube.
2. Create a cleared lysate.
Centrifuge for 2 minutes to pellet the cells. Pour off the supernatant and resuspend the pellet in 30 μl Solution 1 (50 mM Glucose, 25 mM Tris.Cl pH 8, 10 mM EDTA pH 8, 100 μg/ml RNase) .
Add 60 μl Solution 2 (0.2N NaOH, 1% SDS) and mix by shaking. Leave at room temperature for 5 minutes. Add 45 μl Solution 3 (3 M KOAc) , mix by shaking and leave on ice for 10 minutes. Centrifuge for 10 minutes and remove 100 μl of the supernatant to a new Eppendorf tube.
3. Take 10 μl (@20 mg/ml) carboxyl coated magnetic particles, wash three times in 0.5 M EDTA pH 7.2 and resuspend in 10 μl 0.5 M EDTA. Add to the cleared lysate.
4. Add 100 μl of the binding buffer (20% PEG 8000, 2.5 M NaCI) and mix.
5. Allow to incubate at room temperature for 5 minutes. 6. Wash the magnetic particles twice with 5 M NaCI and once with wash buffer (25 mM TrisAcetate pH 7.8, 100 mM KOAc, 10 mM Mg2OAc, 1 mM DTT) . There is no need to resuspend the particles during each wash. 7. Resuspend the particles in 50 μl water and incubate at room temperature for 1 minute.
8. Magnetically separate the particles and remove the DNA to a new tube.
An electrophoretic analysis was done on the cleared lysate after binding to the magnetic microparticles. A complete absence of DNA was observed. An electrophoretic analysis was also done on the elution solution, which showed the purified pUC plasmid.
Example 2 - Double Stranded DNA Isolation using the PEG Induced Precipitate Separation Using a Microtitre Plate
A pUC plasmid (pUC 18, obtained from U.S. Biochemicals Catalog Number 70070) grown in microtitre plates was purified from its host cell by creating a cleared lysate, reversibly binding the plasmid to the magnetic microparticles, separating the magnetic microparticles and then eluting the DNA. The following procedure was used:
1. Grow a single plasmid clone in the well of a microtitre plate containing 300 μl of growth media. 96 different clones may be grown in each plate. Grow the plasmids at 37°C overnight (12-15 hours) shaking at 300rpm.
2. Create a cleared lysate.
Centrifuge for 10 minutes at 3000rpm to pellet the cells.
Aspirate off the supernatant and resuspend the pellet in 30 μl Solution 1 (50 mM Glucose, 25 mM Tris Cl pH 8, 10 mM EDTA pH 8, 100 μg/ml RNase) . Add 60 μl Solution 2 (0.2N NaOH, 1% SDS) and mix by shaking. Leave at room temperature for 5 minutes. Add 45 μl Solution 3 (3 M KOAc) , mix by shaking and leave on ice for 10 minutes. Centrifuge for 15 minutes at 3000rpm and remove
100 μl of the supernatant to a new microtitre plate. 3. Take 10 μl (@ 20 mg/ml) carboxyl coated magnetic particles, wash three times in 0.5 M EDTA pH 7.2 and resuspend in 10 μl 0.5 M EDTA. Add to each well. 4. Add 100 μl of the binding buffer to each well (20% PEG 8000, 2.5 M NaCI) and mix.
5. Allow to incubate at room temperature for 5 minutes.
6. Wash the magnetic particles twice with 5 M NaCI and once with wash buffer (25 mM Tris.Acetate pH 7.8, 100 mM KOAc, 10 mM Mg2OAc, 1 mM DTT) . There is no need to resuspend the particles during each wash.
7. Resuspend the particles in 50 μl water and incubate at room temperature for 1 minute.
8. Magnetically separate the particles and remove the DNA to a new microtitre plate.
This example yields 500-800ng plasmid DNA which is sufficient for thermal cycle DNA sequencing. The advantage of using a microtitre plate is that many samples can be isolated in parallel. As in Example 1, electrophoretic analysis of the cleared lysate after binding to the magnetic microparticles showed no DNA, while electrophoretic analysis of the eluent from microparticles showed purified pUC plasmid.
Example 3 - Isolating Large DNA Vectors From 500 ml Cultures A cosmid (pWE15, obtained from Stratagene, Catalog Number 251201) containing a 35Kb insert and a Bacterial Artificial Chromosome were purified from their host cells by creating a cleared lysate, binding the DNA to the magnetic microparticles, separating the magnetic microparticles from the cleared lysate, and then eluting the DNA. The following procedure was used:
1. Grow a single plasmid clone in 500 ml of growth media. Grow the plasmids at 37°C overnight (12-15 hours) shaking at 300rpm.
2. Create a cleared lysate.
Centrifuge for 10 minutes at 4000rpm to pellet the cells. Pour off the supernatant and aspirate any further liquid. Resuspend the pellet in 3 ml Solution 1 (50 mM Glucose, 25 mM Tris.Cl pH 8, 10 mM EDTA pH 8, 100 μg/ml RNase) .
Add 6 ml Solution 2 (0.2N NaOH, 1% SDS) and mix by shaking. Leave at room temperature for 5 minutes.
Add 4.5 ml Solution 3 (3 M KOAc) , mix by shaking and leave on ice for 15 minutes.
Centrifuge for 15 minutes at 5000rpm and remove 10 ml of the supernatant to a new Falcon tube. (Filter through a 0.45m filter if there are any visible signs of precipitate) .
3. Take 1 ml (@20 mg/ml) carboxyl coated magnetic particles, wash three times in 0.5 M EDTA pH 7.2 and resuspend in 1 ml 0.5 M EDTA. Add to the supernatant. 4. Add 11 ml of the binding buffer to each well (20% PEG 8000, 2.5 M NaCI) and mix.
5. Allow to incubate at room temperature for 15 minutes.
6. Wash the magnetic particles twice with 5 M NaCI and once with wash buffer (25 mM Tris Acetate pH 7.8, 100 mM KOAc, 10 mM Mg2OAc, 1 mM DTT) . There is no need to resuspend the particles during each wash.
7. Resuspend the particles in 1 ml water and incubate at room temperature for 1 minute. 8. Magnetically separate the particles and remove the DNA to a new tube.
Electrophoretic analysis of the solutions obtained from washing the magnetic microparticles with water showed purified cosmid cloned containing the 35Kb insert and the 150Kb BAC (Bacterial Artificial Chromosome) clone which had been cut with Notl to excise the 7Kb vector.
Example 4 - Single Stranded DNA Isolation from Bacteriophages Using the PEG Induced Precipitate Separation Single stranded DNA from M13 clones using E. coli (DH5αF' culture, obtained from U.S. Biochemicals Catalog Number 75112) as a host was isolated by lysing the phage, binding the single stranded DNA to the magnetic microparticles, from separating the magnetic microparticles the supernatant and then eluting the DNA. The following procedure was used:
1. Grov: the M13 clones for 6 hours in 500 μl of lxLB media with a 1/100 dilution an overnight E. coli F' culture. Use of the Beckman deepwell plates will facilitate 96 clones being grown at one time.
2. Centrifuge the growth plate at 3000rpm for 10 minutes to pellet the cells.
3. Add 20 μl of 10% SDS to each well of a Falcon 9311 using a multidispensing pipette. 4. Using a 12 channel pipette, add 100 μl of the phage supernatant to each well, mixing the lysis solution with the supernatant. 5. Incubate the Falcon plate at room temperature for 5 minutes. 6. For a whole plate of 96 clones, remove 1 ml of magnetic particles from the stock and wash three times in 0.5 M EDTA pH 7.2. Take up the washed particles in 1 ml 0.5 M EDTA pH 7.2 and add 10 μl to each well. 7. Add 100 μl of the binding buffer to each well (20% PEG 8000, 2.5 M NaCI) and mix. 8. Incubate the Falcon plate at room temperature for 5 minutes.
9. Wash the magnetic particles twice with 5 M NaCI and once with wash buffer (25 mM Tris Acetate pH 7.8, 100 mM KOAc, 10 mM Mg2OAc, 1 mM DTT) . There is no need to resuspend the particles during each wash.
10. Resuspend the particles in 50 μl water and incubate at room temperature for 1 minute.
11. Magnetically separate the particles and remove the DNA to a new microtitre plate.
Electrophoretic analysis of the solution obtained from washing the magnetic microparticles with water showed purified M13 single stranded DNA.
Example 5 - DNA Sequence from a Plasmid Clone Isolated Using the PEG Induced Precipitate Separation. DNA which had been isolated using the procedure described in example 1 was then sequenced using Taq poly erase and fluorescently labelled primers. The DNA sequence was then electrophoresed on an ABI 373A DNA sequence. The clarity of the data, the read length and the lack of ambiguous bases indicated DNA of high purity.
Example 6 - Selective Removal of DNA From the Solid Phase Based on the Size of the DNA Fragments
DNA isolations may also be performed from amplified DNA such as PCR products. One desirable feature of PCR product purification is the removal of residual nucleotides, oil and excess primers (18-25bp DNA fragments) , which may interfere with subsequent reactions. This example demonstrates the isolation of PCR products as well as the selective removal of the primers during the wash stages.
1. PCR amplify the DNA.
2. Bind the DNA products : Take 10 μl (@20 mg/ml) carboxyl coated magnetic particles, wash three times in 0.5 M EDTA pH 7.2 and resuspend in 10 μl 0.5 M EDTA. Add to the PCR amplifiers.
Add an equal volume of the binding buffer to each reaction (20% PEG 8000, 2.5 M NaCI) and mix.
Allow to incubate at room temperature for 5 minutes.
3. Wash the magnetic particles twice with 5 M NaCI and once with wash buffer (25 mM Tris.Acetate pH 7.8, 100 mM LOAC, 10 mM Mg2OAc, 1 mM DTT) . There is no need to resuspend the particles during each wash.
4. Resuspend the particles in 50 μl water and incubate at room temperature for 1 minute.
5. Magnetically separate the particles and remove the DNA to a new tube.
Electrophoretic analysis of the PCR reaction mixture before binding to the magnetic microparticles showed the presence of primers as well as the final product. Electrophoretic analysis after elution from the magnetic microparticles show that the primers were removed from the amplification product.
Example 7 - DNA Isolation from Agarose Gels Using the PEG Induced Precipitate Separation
DNA fragments were isolated directly from molten agarose plugs. A Lambda marker was cut with HINDIII and electrophoresed. Bands corresponding to 23Kb, 9Kb, 6Kb, 4Kb, and 2Kb and 125bp bands were excised and isolated from the molten agarose according to the following procedure.
1. Electrophorese the DNA samples on a 0.5% agarose gel.
2. Cut out the band of interest. 3. Add 4 volumes of 0.5 x SSC to the agarose plug and melt for 10 minutes at 80°C. 4. Take 10 μl (@ 20 mg/ml) carboxyl coated magnetic particles, wash three times in 0.5 M EDTA pH 7.2 and resuspend in 10 μl 0.5 M EDTA. Add to the supernatant. 5. Add an equal volume of the binding buffer to each well (20% PEG 8000, 2.5 M NaCI) and mix.
6. Allow to incubate at room temperature for 15 minutes.
7. Wash the magnetic particles twice with 5 M NaCI and once with wash buffer (25 mM Tris Acetate pH 7.8, 100 mM KOAc, 10 mM Mg20Ac, 1 mM DTT) . There is no need to resuspend the particles during each wash.
8. Resuspend the particles in 50 μl water and incubate at room temperature for 1 minute.
9. Magnetically separate the particles and remove the DNA to new tube.
Electrophoretic analysis after elution from the magnetic microparticles showed DNA fragments of the sizes excised from the original gel. This approach is rapid and gives the same high yield as the more standard gel extraction applications such as 3-agarose (Eppicenter technologies, WI or Geneclean II (Bio 101 Inc. CA) . Equivalents
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

Claims

CLAIMSWhat is claimed is:
1. A method of reversibly binding polynucieotides non- specifically to magnetic microparticles, comprising the steps of : a) combining magnetic microparticles whose surfaces have bound thereto a functional group which reversibly binds polynucleotide and a solution containing polynucieotides, thereby producing a combination; and b) adjusting the salt and polyalkylene glycol concentration of the combination to a concentration suitable for binding the polynucleotide onto the surfaces of the magnetic microparticles, whereby polynucleotide in the solution binds non-specifically to the magnetic microparticles.
2. The method of Claim 1, wherein the polynucleotide is DNA and the polyalkylene glycol is polyethylene glycol .
3. The method of Claim 2, wherein the polyethylene glycol has a molecular weight of between about 6000 and about 10,000, and wherein the salt is selected from the group consisting of sodium chloride, magnesium chloride, calcium chloride, potassium chloride, lithium chloride, barium chloride and cesium chloride.
4. The method of Claim 3, wherein the concentration of the polyethylene glycol is adjusted to between about 5% and about 15% and wherein the concentration of sodium chloride is adjusted to between about 0.5 M and about 5.0 M.
5. The method of Claim 4, wherein the concentration of the polyethylene glycol is about 10% and the concentration of sodium chloride is about 1.25 M.
6. A method of binding DNA non-specifically to magnetic microparticles, comprising the steps of: a) combining magnetic microparticles whose surfaces have bound thereto a functional group which reversibly binds DNA and a solution containing DNA, thereby producing a combination; and b) adjusting the salt and polyethylene glycol concentration of the combination to a concentration suitable for binding the DNA onto the surfaces of the magnetic microparticles, whereby DNA in the solution binds non-specifically to the magnetic microparticles.
7. The method of Claim 6, wherein the polyethylene glycol has a molecular weight of between 6000 and 10,000, and wherein the salt is selected from the group consisting of sodium chloride, magnesium chloride, calcium chloride, potassium chloride, lithium chloride, barium chloride and cesium chloride.
8. The method of Claim 7, wherein the polyethylene glycol has a molecular weight of about 8000 and the salt is sodium chloride.
9. The method of Claim 8, wherein the concentration of the polyethylene glycol is adjusted to between about 5% and about 15% and wherein the concentration of sodium chloride is adjusted to between about 0.5 M and about 5.0 M.
10. The method of Claim 9, wherein the concentration of the polyethylene glycol is about 10% and the concentration of sodium chloride is about 1.25 M.
11. The method of Claim 10, wherein the DNA solution is a cleared lysate.
12. The method of Claim 10, wherein the DNA solution comprises the reaction product of a PCR amplification.
13. The method of Claim 10, wherein the DNA solution comprises M13 phage DNA, wherein the host cells have been removed.
14. A method of reversibly binding DNA non-specifically to magnetic microparticles having a carboxyl group-coated surface, comprising the steps of: a) combining magnetic microparticles having a carboxyl group-coated surface to a solution containing DNA; and b) adjusting the salt and polyethylene glycol concentration of the solution to a concentration suitable for binding the DNA onto the surfaces of the magnetic microparticles, thereby binding the DNA non-specifically to the magnetic microparticles.
15. The method of Claim 14, wherein the polyethylene glycol has a molecular weight between about 6000 and about 10,000, and wherein the salt is selected from the group consisting of sodium chloride, magnesium chloride, calcium chloride, potassium chloride, lithium chloride, barium chloride and cesium chloride.
16. The method of Claim 15, wherein the polyethylene glycol has a molecular weight of about 8000 and the salt is sodium chloride.
17. The method of Claim 16, wherein the concentration of the polyethylene glycol is adjusted to between about 5% and about 15% and wherein the concentration of sodium chloride is adjusted to between about 0.5 M and about 5.0 M.
18. The method of Claim 17, wherein the concentration of the polyethylene glycol is about 10% and the concentration of sodium chloride is about 1.25 M.
19. The method of Claim 17, wherein the DNA solution is a cleared lysate.
20. The method of Claim 17, wherein the DNA solution comprises the reaction product of a PCR amplification.
21. The method of Claim 17, wherein the DNA solution comprises M13 phage DNA, wherein the host cells have been removed.
22. A method of separating DNA from a solution containing DNA, comprising the steps of: a) combining magnetic microparticles having carboxyl group-coated surfaces and a solution containing DNA, thereby producing a first combination; b) adjusting the salt concentration and the polyethylene glycol concentration of the first combination to concentrations suitable for binding DNA to surfaces of the magnetic microparticles, thereby producing a second combination comprising DNA bound non-specifically to magnetic microparticles; c) separating the magnetic microparticles from the second combination; 5 d) contacting the magnetic microparticles separated in c) with the bound DNA in an elution buffer, whereby DNA is dissolved in the elution buffer and DNA bound from the magnetic microparticles is separated from the magnetic microparticles; and 10 e) separating the magnetic microparticles from the elution buffer.
23. The method of Claim 22, wherein the separation of the magnetic microparticles in steps b) and d) is done magnetically.
15 24. The method of Claim 23, wherein the DNA bound to the magnetic microparticles is washed with a buffer solution, wherein the buffer solution dissolves impurities bound to the magnetic microparticles while leaving the DNA bound to the magnetic microparticles.
20 25. The method of Claim 23, wherein the DNA bound to the magnetic microparticles is washed with a selective elution solution, wherein the selective elution solution dissolves small DNA fragments bound to the microparticles while leaving large DNA fragments bound
25 to the magnetic microparticles.
26. The method of Claim 25, wherein the DNA dissolved by the elution solution is isolated.
27. The method of Claim 24, wherein the DNA is digested by one or more enzymes while bound to the magnetic
30 microparticles.
28. The method of Claim 24, wherein the DNA solution of step a) is a cleared lysate.
29. The method of Claim 24, wherein the DNA of the DNA solution of step a) is the reaction product of a PCR
5 amplification procedure.
30. The method of Claim 24, wherein the DNA solution of step a) comprises M13 phage DNA, wherein the host cells have been removed.
31. The method of Claim 24, wherein the DNA solution of 10 step a) comprises DNA of interest, wherein the DNA of interest has been separated from undesired DNA by electrophoresis in an agarose gel, and a melted agarose plug excised from the electrophoresis gel, wherein the agarose plug contains the DNA of interest.
15 32. A method of separating DNA from a solution containing DNA, comprising the steps of: a) combining a solution containing DNA and carboxyl group-coated magnetic micro-particles, thereby producing a first combination;
20 b) combining the first combination with sufficient quantities of polyethylene glycol and sodium chloride to produce a second combination having a final polyethylene glycol concentration of from about 5% to about 15% and a final sodium chloride 5 concentration of from about 0.5 M to about 5.0 M, whereby DNA in the solution binds nonspecifically to the magnetic microparticles, producing magnetic microparticles having DNA bound thereto; c) separating magnetic microparticles from the second 0 combination, thereby producing separated magnetic microparticles having DNA bound thereto; d) contacting the separated magnetic microparticles having DNA bound thereto with an elution buffer, whereby the DNA is released from the magnetic microparticles and an elution buffer containing
5 DNA and magnetic microparticles is produced; and e) separating DNA released from the magnetic microparticles from the elution buffer.
33. The method of Claim 32, wherein the polyethylene glycol has a molecular weight of between about 6000 and about
10 10,000 and wherein the salt is selected from the group consisting of sodium chloride, magnesium chloride, calcium chloride, potassium chloride, lithium chloride, barium chloride and cesium chloride.
34. The method of Claim 33, wherein the polyethylene glycol 15 has a molecular weight of about 8000 and the salt is sodium chloride.
35. The method of Claim 34, wherein the concentration of the polyethylene glycol is adjusted to between about 5% and about 15% and wherein the concentration of sodium
20 chloride is adjusted to between about 0.5 M and about 5.0 M.
36. The method of Claim 35, wherein the concentration of the polyethylene glycol is about 10% and the concentration of sodium chloride is about 1.25 M.
25 37. A method of determining the nucleotide sequence of a
DNA molecule, comprising binding the DNA molecule non- specifically to magnetic microparticles having a carboxyl group-coated surface by the method of Claim 17 and sequencing the DNA while the DNA is bound to the
30 magnetic microparticles.
38. A kit comprising a binding buffer and magnetic microparticles with carboxyl group-coated surfaces, wherein the binding buffer comprises a suitable salt and a suitable polyethylene glycol at a concentration suitable for binding DNA to the surface of the magnetic microparticles .
39. The kit of Claim 38, wherein the kit further comprises a suitable elution buffer, wherein the elution buffer is capable of dissolving DNA bound to the magnetic microparticles.
40. The kit of Claim 39, wherein the kit additionally comprises a wash buffer, wherein the wash buffer is capable of dissolving impurities bound to magnetic microparticles but is incapable of dissolving DNA bound to magnetic microparticles.
41. The kit of Claim 39, wherein the kit additionally comprises reagents necessary for clearing a cell lysate .
42. A method of isolating polynucieotides from a solution containing a mixture of biomolecules, comprising the steps of : a) combining a solution containing a mixture of biomolecules with carboxyl-coated magnetic microparticles; b) adjusting the polarity and the hydrophobicity of the resulting solution so as to adsorb polynucieotides onto the surface of the microparticles; c) separating the microparticles from the solution containing the biomolecules; d) combining the separated magnetic microparticles with a second solution whose polarity and hydrophobicity results in the polynucieotides being desorbed from the surface of the magnetic microparticle, and dissolved in the second solution; and e) separating the magnetic microparticles from the second solution.
PCT/US1995/011839 1994-09-20 1995-09-19 Dna purification and isolation using a solid phase WO1996009379A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/309,267 US5705628A (en) 1994-09-20 1994-09-20 DNA purification and isolation using magnetic particles
US08/309,267 1994-09-20

Publications (1)

Publication Number Publication Date
WO1996009379A1 true WO1996009379A1 (en) 1996-03-28

Family

ID=23197456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/011839 WO1996009379A1 (en) 1994-09-20 1995-09-19 Dna purification and isolation using a solid phase

Country Status (3)

Country Link
US (2) US5705628A (en)
IL (1) IL115352A (en)
WO (1) WO1996009379A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0885958A1 (en) * 1996-02-25 1998-12-23 Precision System Science Co., Ltd. Method for treating biopolymers, microorganisms or materials by using more than one type of magnetic particles
WO1999058664A1 (en) * 1998-05-14 1999-11-18 Whitehead Institute For Biomedical Research Solid phase technique for selectively isolating nucleic acids
EP1002860A1 (en) * 1998-10-30 2000-05-24 Becton Dickinson and Company Method for purification and manipulation of nucleic acids using paramagnetic particles
WO2001040459A2 (en) * 1999-12-03 2001-06-07 InViTek Gesellschaft für Biotechnik & Biodesign mbH Surface modified supporting materials for binding biological materials, method for the production and use thereof
WO2001046404A1 (en) * 1999-12-22 2001-06-28 Abbott Laboratories Nucleic acid isolation method and kit
WO2001059098A2 (en) * 2000-02-11 2001-08-16 Eppendorf Ag Method for purifying nucleic acids
WO2003040687A2 (en) 2001-11-06 2003-05-15 Cortex Biochem, Inc. Isolation and purification of nucleic acids
EP1368629A1 (en) * 2001-02-16 2003-12-10 Cortex Biochem Inc. Magnetic isolation and purification of nucleic acids
WO2005089929A2 (en) 2004-03-18 2005-09-29 Ambion , Inc. Modified surfaces as solid supports for nucleic acid purification
US7081192B1 (en) * 2000-08-08 2006-07-25 Aviva Biosciences Corporation Methods for manipulating moieties in microfluidic systems
US7119194B2 (en) 1995-07-07 2006-10-10 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
EP1799847A2 (en) * 2004-09-16 2007-06-27 Lumigen, Inc. Simplified methods for isolating nucleic acids from cellular materials
EP1799846A2 (en) * 2004-09-16 2007-06-27 Lumigen, Inc. Methods for isolating nucleic acids from biological and cellular materials
DE102007009347A1 (en) 2007-02-27 2008-08-28 Agowa Gmbh Isolating nucleic acids comprises binding the nucleic acids adsorbtive to polar surfaces, washing the surfaces with substances solution after removing the binding mixture, which have an affinity to polar surfaces and to the nuclei acids
US7527929B2 (en) 2004-07-30 2009-05-05 Agencourt Bioscience Corporation Methods of isolating nucleic acids using multifunctional group-coated solid phase carriers
WO2009070465A1 (en) * 2007-11-29 2009-06-04 New England Biolabs, Inc. Selective purification of small rnas from mixtures
GB2455780A (en) * 2007-12-21 2009-06-24 Zainulabedin Mohamedali Saiyed Nucleic acid separation
EP2157181A1 (en) 2008-08-13 2010-02-24 AGOWA Gesellschaft für molekularbiologische Technologie mbH Method for isolating nucleic acids and test kit
US8026068B2 (en) 2002-01-08 2011-09-27 Roche Molecular Systems, Inc. Use of silica material in an amplification reaction
WO2012069660A1 (en) * 2010-11-26 2012-05-31 Invitrogen Dynal As Use of polyols in nucleic acid processing
EP2969140A1 (en) * 2013-03-15 2016-01-20 Abbott Molecular Inc. One-step procedure for the purification of nucleic acids
WO2016077294A1 (en) * 2014-11-14 2016-05-19 Corning Incorporated Methods and kits for post-ivt rna purification
WO2016079509A1 (en) * 2014-11-18 2016-05-26 Cambridge Epigenetix Limited Methods for nucleic acid isolation
EP3061823A1 (en) * 2015-02-25 2016-08-31 QIAGEN GmbH Method for extracting nucleic acids from an agarose matrix
EP3141298A1 (en) 2015-09-09 2017-03-15 National Center For Scientific Research "Demokritos" Polymeric microfluidic device for nucleic acid purification fabricated via plasma micro-nanotexturing
WO2018109075A1 (en) * 2016-12-15 2018-06-21 Qiagen Gmbh Method for isolating highly pure nucleic acid with magnetic particles
US10344274B2 (en) 2016-02-16 2019-07-09 Life Magnetics, Inc. Methods for separating nucleic acids with graphene coated magnetic beads
WO2020260620A1 (en) * 2019-06-28 2020-12-30 Qiagen Gmbh Method for enriching nucleic acids by size
WO2020260618A1 (en) * 2019-06-28 2020-12-30 Qiagen Gmbh Method for separating nucleic acid molecules by size
WO2021122846A1 (en) * 2019-12-16 2021-06-24 Qiagen Gmbh Enrichment method

Families Citing this family (346)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425138D0 (en) * 1994-12-12 1995-02-08 Dynal As Isolation of nucleic acid
KR100463475B1 (en) 1995-06-08 2005-06-22 로셰 디아그노스틱스 게엠베하 Magnetic Pigment
DE19520398B4 (en) * 1995-06-08 2009-04-16 Roche Diagnostics Gmbh Magnetic pigment
US20020031771A1 (en) * 1995-12-07 2002-03-14 Short Jay M. Sequence based screening
EP0929694A4 (en) * 1996-03-15 2002-05-02 Penn State Res Found Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
US6251691B1 (en) 1996-04-25 2001-06-26 Bioarray Solutions, Llc Light-controlled electrokinetic assembly of particles near surfaces
JP2001502179A (en) * 1996-10-15 2001-02-20 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション Compositions and methods for rapid isolation of plasmid DNA
US6017457A (en) * 1996-11-13 2000-01-25 Transgenomic, Inc. Method for performing polynucleotide separations using liquid chromatography
US5997742A (en) * 1996-11-13 1999-12-07 Transgenomic, Inc. Method for performing polynucleotide separations using liquid chromatography
US6030527A (en) * 1996-11-13 2000-02-29 Transgenomic, Inc. Apparatus for performing polynucleotide separations using liquid chromatography
US6174441B1 (en) 1996-11-13 2001-01-16 Transgenomic, Inc. Method for performing polynucleotide separations using liquid chromatography
US5986085A (en) * 1997-04-25 1999-11-16 Transgenomic, Inc. Matched ion polynucleotide chromatography (MIPC) process for separation of polynucleotide fragments
US6177559B1 (en) * 1998-04-24 2001-01-23 Transgenomic, Inc. Process for separation of polynucleotide fragments
JP2000516638A (en) 1997-06-10 2000-12-12 トランスジエノミツク・インコーポレーテツド Systems and methods for performing polynucleotide separation using liquid chromatography
DE19743518A1 (en) * 1997-10-01 1999-04-15 Roche Diagnostics Gmbh Automated, universally applicable sample preparation method
US6914137B2 (en) * 1997-12-06 2005-07-05 Dna Research Innovations Limited Isolation of nucleic acids
ATE218140T1 (en) * 1997-12-06 2002-06-15 Dna Res Innovations Ltd ISOLATION OF NUCLEIC ACIDS
US6265168B1 (en) 1998-10-06 2001-07-24 Transgenomic, Inc. Apparatus and method for separating and purifying polynucleotides
US7078224B1 (en) 1999-05-14 2006-07-18 Promega Corporation Cell concentration and lysate clearance using paramagnetic particles
FI990082A0 (en) * 1999-01-18 1999-01-18 Labsystems Oy Purification process using magnetic particles
EP1147226B1 (en) * 1999-01-27 2013-01-23 Folim G. Halaka Materials and methods for the purification of polyelectrolytes
CA2270106C (en) 1999-04-23 2006-03-14 Yousef Haj-Ahmad Nucleic acid purification and process
US6310199B1 (en) * 1999-05-14 2001-10-30 Promega Corporation pH dependent ion exchange matrix and method of use in the isolation of nucleic acids
EP1621618B1 (en) * 1999-05-14 2011-10-26 Promega Corporation Cell concentration and lysate clearance using paramagnetic particles
JP4551568B2 (en) * 1999-05-14 2010-09-29 プロメガ コーポレイション Cell collection and lysate clarification using paramagnetic particles
AU6281200A (en) * 1999-08-09 2001-03-05 Bilatec Ag Laboratory robot and method and reagent kit for isolating nucleic acids
DE19943374A1 (en) * 1999-09-10 2001-03-29 Max Planck Gesellschaft Method for binding nucleic acids to a solid phase
ES2256068T3 (en) * 1999-11-17 2006-07-16 Roche Diagnostics Gmbh MAGNETIC GLASS PARTICLES, METHOD FOR THEIR PREPARATION AND USES OF THE SAME.
AU2440101A (en) * 1999-12-20 2001-07-03 Ligochem, Inc. The removal of extraneous substances from biological fluids containing nucleic acids and the recovery of nucleic acids
US9709559B2 (en) 2000-06-21 2017-07-18 Bioarray Solutions, Ltd. Multianalyte molecular analysis using application-specific random particle arrays
EP1311839B1 (en) 2000-06-21 2006-03-01 Bioarray Solutions Ltd Multianalyte molecular analysis using application-specific random particle arrays
DE10033583A1 (en) * 2000-07-11 2002-01-24 Bayer Ag Superparamagnetic polymer beads
US20030228600A1 (en) * 2000-07-14 2003-12-11 Eppendorf 5 Prime, Inc. DNA isolation method and kit
US6548256B2 (en) 2000-07-14 2003-04-15 Eppendorf 5 Prime, Inc. DNA isolation method and kit
US20030082605A1 (en) * 2000-09-06 2003-05-01 Hodge Timothy A. Genomic DNA detection method and system thereof
US20050272085A1 (en) * 2000-09-06 2005-12-08 Hodge Timothy A Methods for forensic and congenic screening
US7494817B2 (en) * 2000-09-06 2009-02-24 Transnet Yx, Inc. Methods for genotype screening using magnetic particles
US20050266494A1 (en) * 2000-09-06 2005-12-01 Hodge Timothy A System and method for computer network ordering of biological testing
EP1978110B1 (en) * 2000-09-06 2010-05-26 Transnetyx, Inc. Computer-based method and system for screening genomic DNA
US20030087286A1 (en) * 2000-09-06 2003-05-08 Hodge Timothy A. Isolation of eukaryotic genomic DNA using magnetically responsive solid functionalized particles
US20050239125A1 (en) 2000-09-06 2005-10-27 Hodge Timothy A Methods for genotype screening
US20020106686A1 (en) * 2001-01-09 2002-08-08 Mckernan Kevin J. Methods and reagents for the isolation of nucleic acids
DE10104025B4 (en) * 2001-01-31 2008-07-10 Qiagen North American Holdings, Inc. Process for the purification and subsequent amplification of double-stranded DNA
US6855499B1 (en) 2001-02-16 2005-02-15 Cortex Biochem, Inc. Magnetic isolation and purification of nucleic acids
CN1152055C (en) * 2001-03-20 2004-06-02 清华大学 Surface cladding and radical functino modification method of magnetic microsphere, thus obtained microsphere and its application
GB0108287D0 (en) * 2001-04-03 2001-05-23 Imp College Innovations Ltd Methods of crystal optimisation
WO2002099824A2 (en) * 2001-04-16 2002-12-12 Zornes David A Nanotube deposition on adsorbents in water maker heat pump
AU2002320058A1 (en) * 2001-06-06 2002-12-16 The General Hspital Corporation Magnetic-nanoparticle conjugates and methods of use
US7262063B2 (en) 2001-06-21 2007-08-28 Bio Array Solutions, Ltd. Directed assembly of functional heterostructures
US20060014186A1 (en) * 2001-09-04 2006-01-19 Hodge Timothy A Methods for genotype screening of a strain disposed on an adsorbent carrier
US20040137449A1 (en) * 2001-10-05 2004-07-15 Nargessi R D Magnetic isolation and purification of nucleic acids
US7253609B2 (en) * 2001-10-08 2007-08-07 Dr. Johannes Heidenhain Gmbh Encapsulated measuring apparatus for detecting a velocity and/or acceleration of a rotationally or linearly moved component
US20040002073A1 (en) 2001-10-15 2004-01-01 Li Alice Xiang Multiplexed analysis of polymorphic loci by concurrent interrogation and enzyme-mediated detection
US6667165B2 (en) 2001-11-13 2003-12-23 Eppendorf Ag Method and compositions for reversible inhibition of thermostable polymerases
JP4106026B2 (en) * 2001-11-28 2008-06-25 アプレラ コーポレイション Selective nucleic acid isolation methods and compositions
AU2003202026A1 (en) 2002-01-16 2003-09-02 Dynal Biotech Asa Method for isolating nucleic acids and protein from a single sample
US7052840B2 (en) * 2002-04-03 2006-05-30 Capitol Genomix, Inc. Reversible association of nucleic acid with a carboxylated substrate
US7202907B2 (en) * 2002-04-09 2007-04-10 Zoran Corporation 2:2 and 3:2 pull-down detection techniques
GB0210766D0 (en) * 2002-05-10 2002-06-19 Genovision As Isolating nucleic acid
GB0215185D0 (en) 2002-07-01 2002-08-07 Genovision As Binding a target substance
AU2003291931A1 (en) 2002-11-08 2004-06-07 Invitek Gesellschaft Fur Biotechnik And Biodesign Mbh Novel buffer formulations for isolating, purifying and recovering long-chain and short-chain nucleic acids
US7526114B2 (en) 2002-11-15 2009-04-28 Bioarray Solutions Ltd. Analysis, secure access to, and transmission of array images
GB0229287D0 (en) * 2002-12-16 2003-01-22 Dna Res Innovations Ltd Polyfunctional reagents
US7893222B2 (en) * 2002-12-20 2011-02-22 University Of Houston Introduction of structural affinity handles as a tool in selective nucleic acid separations
CA2515075C (en) * 2003-02-05 2012-10-02 Iquum, Inc. Sample processing
US20040157219A1 (en) * 2003-02-06 2004-08-12 Jianrong Lou Chemical treatment of biological samples for nucleic acid extraction and kits therefor
US7601491B2 (en) * 2003-02-06 2009-10-13 Becton, Dickinson And Company Pretreatment method for extraction of nucleic acid from biological samples and kits therefor
US20040197780A1 (en) * 2003-04-02 2004-10-07 Agencourt Bioscience Corporation Method for isolating nucleic acids
US20140011201A1 (en) * 2003-05-13 2014-01-09 Ibis Biosciences, Inc. Method for the purification of targeted nucleic acids from background nucleic acids
TWI303275B (en) * 2003-05-30 2008-11-21 Advisys Inc Devices and methods for biomaterial production
US20050277204A1 (en) * 2003-08-12 2005-12-15 Massachusetts Institute Of Technology Sample preparation methods and devices
US20050118570A1 (en) * 2003-08-12 2005-06-02 Massachusetts Institute Of Technology Sample preparation methods and devices
EP1510577A1 (en) 2003-08-29 2005-03-02 Qiagen GmbH Method for magnetic bead isolation of nucleic acids
US7927796B2 (en) 2003-09-18 2011-04-19 Bioarray Solutions, Ltd. Number coding for identification of subtypes of coded types of solid phase carriers
WO2005031305A2 (en) 2003-09-22 2005-04-07 Bioarray Solutions, Ltd. Surface immobilized polyelectrolyte with multiple functional groups capable of covalently bonding to biomolecules
US20050072674A1 (en) * 2003-10-03 2005-04-07 Agencourt Bioscience Corporation Method and device for introducing a sample into an electrophoretic apparatus
US7563569B2 (en) 2003-10-28 2009-07-21 Michael Seul Optimization of gene expression analysis using immobilized capture probes
JP2007509629A (en) 2003-10-29 2007-04-19 バイオアレイ ソリューションズ リミテッド Complex nucleic acid analysis by cleavage of double-stranded DNA
WO2005061724A1 (en) * 2003-12-10 2005-07-07 The General Hospital Corporation Self-assembling nanoparticle conjugates
US20050266394A1 (en) * 2003-12-24 2005-12-01 Massachusette Institute Of Technology Magnetophoretic cell clarification
KR20050071751A (en) * 2004-01-02 2005-07-08 삼성전자주식회사 A method for isolating a nucleic acid by using a carbon nanotube
KR101077603B1 (en) * 2004-01-28 2011-10-27 삼성전자주식회사 A method for amplifying a nucleic acid using a solid phase material coated with a carboxyl group or amino group
US20050181378A1 (en) * 2004-02-18 2005-08-18 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
US20060160122A1 (en) * 2004-02-18 2006-07-20 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
US20050196856A1 (en) * 2004-02-18 2005-09-08 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
JP2005292007A (en) * 2004-04-01 2005-10-20 Seiko Epson Corp Nucleic acid immobilizing method, and manufacturing method for biosensor using same
US20050239091A1 (en) * 2004-04-23 2005-10-27 Collis Matthew P Extraction of nucleic acids using small diameter magnetically-responsive particles
JP4476050B2 (en) * 2004-06-30 2010-06-09 株式会社ニデック Perimeter
US7848889B2 (en) 2004-08-02 2010-12-07 Bioarray Solutions, Ltd. Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification
JP2008511816A (en) * 2004-08-03 2008-04-17 ベクトン・ディキンソン・アンド・カンパニー Use of magnetic materials to separate samples
AU2005271688B2 (en) * 2004-08-03 2011-10-06 Becton, Dickinson And Company Use of magnetic material to direct isolation of compounds and fractionation of multipart samples
JP4810164B2 (en) * 2004-09-03 2011-11-09 富士フイルム株式会社 Nucleic acid separation and purification method
CN102759466A (en) * 2004-09-15 2012-10-31 英特基因有限公司 Microfluidic devices
US7166680B2 (en) * 2004-10-06 2007-01-23 Advanced Cardiovascular Systems, Inc. Blends of poly(ester amide) polymers
EP1650297B1 (en) * 2004-10-19 2011-04-13 Samsung Electronics Co., Ltd. Method and apparatus for the rapid disruption of cells or viruses using micro magnetic beads and laser
KR100601972B1 (en) 2004-11-03 2006-07-18 삼성전자주식회사 Apparatus and method for the purification of nucleic acids by phase separation using Laser and beads
KR100601974B1 (en) * 2004-11-25 2006-07-18 삼성전자주식회사 Apparatus and method for the purification of nucleic acids by different laser absorption of beads
KR100624450B1 (en) 2004-12-10 2006-09-18 삼성전자주식회사 Isolation and purification method of biomolecules using hydrogel
KR100624452B1 (en) * 2004-12-21 2006-09-18 삼성전자주식회사 Method for isolating and purifying nucleic acids using immobilized hydrogel or PEG-hydrogel co-polymer
US8288169B2 (en) * 2005-01-21 2012-10-16 Argylla Technologies Surface mediated self-assembly of nanoparticles
JP2008528040A (en) 2005-02-01 2008-07-31 アジェンコート バイオサイエンス コーポレイション Reagents, methods and libraries for bead-based sequencing
EP2233582A1 (en) 2005-02-01 2010-09-29 AB Advanced Genetic Analysis Corporation Nucleic acid sequencing by performing successive cycles of duplex extension
US8569477B2 (en) 2005-02-11 2013-10-29 Life Technologies As Method for isolating nucleic acids comprising the use of ethylene glycol multimers
US20060186110A1 (en) * 2005-02-22 2006-08-24 Mark Campello Electric heater with resistive carbon heating elements
US20060234251A1 (en) * 2005-04-19 2006-10-19 Lumigen, Inc. Methods of enhancing isolation of RNA from biological samples
US20070105181A1 (en) * 2005-05-04 2007-05-10 Invitrogen Corporation Identification of cancer biomarkers and phosphorylated pdroteins
EP2471805A3 (en) 2005-05-06 2013-01-16 Gen-Probe Incorporated Compositions and assays to specifically detect nucleic acid of influenza virus A or B
US8486629B2 (en) 2005-06-01 2013-07-16 Bioarray Solutions, Ltd. Creation of functionalized microparticle libraries by oligonucleotide ligation or elongation
DE102005025640A1 (en) * 2005-06-03 2006-12-07 Scienion Ag Microdispenser and associated operating method
JP2008546424A (en) * 2005-06-28 2008-12-25 アジェンコート パーソナル ジェノミクス コーポレイション Methods for making and sequencing modified polynucleotides
JP2009500019A (en) * 2005-07-01 2009-01-08 プロメガ・コーポレーション Suspended particle network for the purification of biomolecules, and the use of buoyant particles or buoyant particle networks for the purification of biomolecules
US20070026435A1 (en) * 2005-07-28 2007-02-01 Polysciences, Inc. Hydroxysilane functionalized magnetic particles and nucleic acid separation method
AU2006284832B2 (en) * 2005-08-31 2011-06-02 T2 Biosystems Inc. NMR device for detection of analytes involving magnetic particles
US7727473B2 (en) 2005-10-19 2010-06-01 Progentech Limited Cassette for sample preparation
US7754148B2 (en) 2006-12-27 2010-07-13 Progentech Limited Instrument for cassette for sample preparation
KR101157174B1 (en) * 2005-11-24 2012-06-20 삼성전자주식회사 Method and apparatus for rapidly lysing cells or virus
US8030034B2 (en) * 2005-12-09 2011-10-04 Promega Corporation Nucleic acid purification with a binding matrix
EP1979079A4 (en) * 2006-02-03 2012-11-28 Integenx Inc Microfluidic devices
US20080003564A1 (en) * 2006-02-14 2008-01-03 Iquum, Inc. Sample processing
WO2007111937A1 (en) 2006-03-23 2007-10-04 Applera Corporation Directed enrichment of genomic dna for high-throughput sequencing
US20090062129A1 (en) * 2006-04-19 2009-03-05 Agencourt Personal Genomics, Inc. Reagents, methods, and libraries for gel-free bead-based sequencing
EP3617321A3 (en) 2006-05-31 2020-04-29 Sequenom, Inc. Methods and compositions for the extraction and amplification of nucleic acid from a sample
US20080026374A1 (en) * 2006-07-31 2008-01-31 Sigma Aldrich Co. Compositions and Methods for Isolation of Biological Molecules
US20080026375A1 (en) * 2006-07-31 2008-01-31 Sigma Aldrich Co. Compositions and Methods for Isolation of Biological Molecules
US20080023395A1 (en) * 2006-07-31 2008-01-31 Sigma Aldrich Co. Compositions and Methods for Isolation of Biological Molecules
US20080044884A1 (en) * 2006-08-21 2008-02-21 Samsung Electronics Co., Ltd. Method and device for separating cells from a sample using a nonplanar solid substrate
US8158411B2 (en) * 2006-08-21 2012-04-17 Samsung Electronics Co., Ltd. Method of separating microorganism using nonplanar solid substrate and device for separating microorganism using the same
JP2011503244A (en) * 2006-12-21 2011-01-27 インヴィトロジェン ダイナル エーエス Particles and their use in nucleic acid isolation methods or phosphorylated protein isolation methods
JP2008167722A (en) * 2007-01-15 2008-07-24 Konica Minolta Medical & Graphic Inc Nucleic acid isolation method by heating on magnetic support
CN101715483A (en) * 2007-02-05 2010-05-26 微芯片生物工艺学股份有限公司 microfluidic and nanofluidic devices, systems, and applications
WO2008101192A1 (en) * 2007-02-16 2008-08-21 Applied Biosystems, Llc Method for recovering nucleic acid from a mixed cell suspension, without centrifugation
US20100190240A1 (en) * 2007-03-21 2010-07-29 Ibis Biosciences, Inc. Reagents for nucleic acid purification
US9458451B2 (en) 2007-06-21 2016-10-04 Gen-Probe Incorporated Multi-channel optical measurement instrument
JP5232858B2 (en) * 2007-06-29 2013-07-10 ベクトン・ディキンソン・アンド・カンパニー Method for extracting and purifying components of biological samples
CN103443275B (en) * 2007-07-23 2016-03-16 应用生物系统有限责任公司 The method of spermanucleic acid is reclaimed by forensic samples
US9097644B2 (en) * 2007-08-17 2015-08-04 Massachusetts Institute Of Technology Magnetic resonance-based viscometers and methods
EP2191012A1 (en) * 2007-09-21 2010-06-02 Streck, Inc. Nucleic acid isolation in preserved whole blood
WO2009046149A1 (en) * 2007-10-01 2009-04-09 Applied Biosystems Inc. Chase ligation sequencing
US8685322B2 (en) * 2007-11-13 2014-04-01 Stratec Biomedical Ag Apparatus and method for the purification of biomolecules
US8815576B2 (en) * 2007-12-27 2014-08-26 Lawrence Livermore National Security, Llc. Chip-based sequencing nucleic acids
US20090253181A1 (en) * 2008-01-22 2009-10-08 Microchip Biotechnologies, Inc. Universal sample preparation system and use in an integrated analysis system
JP5693449B2 (en) 2008-04-30 2015-04-01 グラダリス インク.Gradalis, Inc. High-purity plasmid DNA preparation and preparation method thereof
EP2163621A1 (en) * 2008-09-03 2010-03-17 Qiagen GmbH Method for isolating and cleaning nucleic acids
DE102008047790A1 (en) * 2008-09-17 2010-04-15 Qiagen Gmbh Method for normalizing the content of biomolecules in a sample
US8672532B2 (en) * 2008-12-31 2014-03-18 Integenx Inc. Microfluidic methods
US8368882B2 (en) 2009-01-30 2013-02-05 Gen-Probe Incorporated Systems and methods for detecting a signal and applying thermal energy to a signal transmission element
EP2394175B1 (en) * 2009-02-09 2016-02-03 caprotec bioanalytics GmbH Devices, systems and methods for separating magnetic particles
EP3211095B1 (en) 2009-04-03 2019-01-02 Sequenom, Inc. Nucleic acid preparation compositions and methods
CN113145298B (en) 2009-05-15 2023-09-22 简·探针公司 Method and apparatus for automatic movement of magnet in instrument for performing magnetic separation process
US8388908B2 (en) * 2009-06-02 2013-03-05 Integenx Inc. Fluidic devices with diaphragm valves
WO2010141921A1 (en) 2009-06-05 2010-12-09 Integenx Inc. Universal sample preparation system and use in an integrated analysis system
US8222397B2 (en) 2009-08-28 2012-07-17 Promega Corporation Methods of optimal purification of nucleic acids and kit for use in performing such methods
US8039613B2 (en) * 2009-08-28 2011-10-18 Promega Corporation Methods of purifying a nucleic acid and formulation and kit for use in performing such methods
WO2011026030A1 (en) * 2009-08-31 2011-03-03 Mbio Diagnostics Corporation Integrated sample preparation and analyte detection
US10174368B2 (en) 2009-09-10 2019-01-08 Centrillion Technology Holdings Corporation Methods and systems for sequencing long nucleic acids
US10072287B2 (en) 2009-09-10 2018-09-11 Centrillion Technology Holdings Corporation Methods of targeted sequencing
US8536322B2 (en) * 2009-10-19 2013-09-17 Zhiqiang Han Method for nucleic acid isolation by solid phase reversible binding of nucleic acids
TWI407994B (en) 2009-10-22 2013-09-11 Ind Tech Res Inst Method, agent, and kit for isolating nucleic acids
US8584703B2 (en) 2009-12-01 2013-11-19 Integenx Inc. Device with diaphragm valve
EP2513335A4 (en) * 2009-12-14 2013-09-11 Betty Wu Method and materials for separating nucleic acid materials
CN105004596B (en) 2010-02-23 2018-12-21 卢米尼克斯公司 Instrument and method for the sample preparation of integration, reaction and detection
US20110223588A1 (en) * 2010-03-09 2011-09-15 Biosample Llc Solid Phase Nucleic Acid Extraction From Small Sample Volumes, and Release of Controlled Quantities
US8512538B2 (en) 2010-05-28 2013-08-20 Integenx Inc. Capillary electrophoresis device
US9186668B1 (en) 2010-06-04 2015-11-17 Sandia Corporation Microfluidic devices, systems, and methods for quantifying particles using centrifugal force
US8945914B1 (en) 2010-07-08 2015-02-03 Sandia Corporation Devices, systems, and methods for conducting sandwich assays using sedimentation
US9795961B1 (en) * 2010-07-08 2017-10-24 National Technology & Engineering Solutions Of Sandia, Llc Devices, systems, and methods for detecting nucleic acids using sedimentation
US8962346B2 (en) 2010-07-08 2015-02-24 Sandia Corporation Devices, systems, and methods for conducting assays with improved sensitivity using sedimentation
EP2593569B1 (en) 2010-07-12 2018-01-03 Gen-Probe Incorporated Compositions and assays to detect seasonal h1 influenza a virus nucleic acids
US9046507B2 (en) 2010-07-29 2015-06-02 Gen-Probe Incorporated Method, system and apparatus for incorporating capacitive proximity sensing in an automated fluid transfer procedure
US20130040375A1 (en) 2011-08-08 2013-02-14 Tandem Diagnotics, Inc. Assay systems for genetic analysis
US20120034603A1 (en) 2010-08-06 2012-02-09 Tandem Diagnostics, Inc. Ligation-based detection of genetic variants
US11031095B2 (en) 2010-08-06 2021-06-08 Ariosa Diagnostics, Inc. Assay systems for determination of fetal copy number variation
US11203786B2 (en) 2010-08-06 2021-12-21 Ariosa Diagnostics, Inc. Detection of target nucleic acids using hybridization
US8700338B2 (en) 2011-01-25 2014-04-15 Ariosa Diagnosis, Inc. Risk calculation for evaluation of fetal aneuploidy
US20130261003A1 (en) 2010-08-06 2013-10-03 Ariosa Diagnostics, In. Ligation-based detection of genetic variants
US20140342940A1 (en) 2011-01-25 2014-11-20 Ariosa Diagnostics, Inc. Detection of Target Nucleic Acids using Hybridization
US10533223B2 (en) 2010-08-06 2020-01-14 Ariosa Diagnostics, Inc. Detection of target nucleic acids using hybridization
US10167508B2 (en) 2010-08-06 2019-01-01 Ariosa Diagnostics, Inc. Detection of genetic abnormalities
EP2606242A4 (en) 2010-08-20 2016-07-20 Integenx Inc Microfluidic devices with mechanically-sealed diaphragm valves
WO2012024658A2 (en) 2010-08-20 2012-02-23 IntegenX, Inc. Integrated analysis system
US8563298B2 (en) 2010-10-22 2013-10-22 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
US8409807B2 (en) 2010-10-22 2013-04-02 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
ES2576927T3 (en) 2010-10-22 2016-07-12 T2 Biosystems, Inc. NMR systems and methods for rapid analyte detection
EP2646551B1 (en) 2010-11-30 2017-06-07 Life Technologies Corporation Alkylene glycols and polymers and copolymers thereof for direct isolation of nucleic acid from embedded samples
US10131947B2 (en) 2011-01-25 2018-11-20 Ariosa Diagnostics, Inc. Noninvasive detection of fetal aneuploidy in egg donor pregnancies
US9994897B2 (en) 2013-03-08 2018-06-12 Ariosa Diagnostics, Inc. Non-invasive fetal sex determination
US8756020B2 (en) 2011-01-25 2014-06-17 Ariosa Diagnostics, Inc. Enhanced risk probabilities using biomolecule estimations
US11270781B2 (en) 2011-01-25 2022-03-08 Ariosa Diagnostics, Inc. Statistical analysis for non-invasive sex chromosome aneuploidy determination
US20120252682A1 (en) 2011-04-01 2012-10-04 Maples Corporate Services Limited Methods and systems for sequencing nucleic acids
AU2012250619B2 (en) 2011-05-04 2015-11-26 Luminex Corporation Apparatus and methods for integrated sample preparation, reaction and detection
US8712697B2 (en) 2011-09-07 2014-04-29 Ariosa Diagnostics, Inc. Determination of copy number variations using binomial probability calculations
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
CA2849354C (en) 2011-09-26 2021-11-09 Preanalytix Gmbh Stabilisation and isolation of extracellular nucleic acids
CN104080958A (en) 2011-10-19 2014-10-01 纽亘技术公司 Compositions and methods for directional nucleic acid amplification and sequencing
US20150136604A1 (en) 2011-10-21 2015-05-21 Integenx Inc. Sample preparation, processing and analysis systems
US10865440B2 (en) 2011-10-21 2020-12-15 IntegenX, Inc. Sample preparation, processing and analysis systems
US9340828B2 (en) 2011-10-27 2016-05-17 Ge Healthcare Bio-Sciences Ab Purification of nucleic acid
US9441265B2 (en) 2011-12-29 2016-09-13 Ibis Biosciences, Inc. Compositions and methods for sample preparation
GB2513793B (en) 2012-01-26 2016-11-02 Nugen Tech Inc Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation
US9244065B1 (en) 2012-03-16 2016-01-26 Sandia Corporation Systems, devices, and methods for agglutination assays using sedimentation
US9562271B2 (en) 2012-04-20 2017-02-07 T2 Biosystems, Inc. Compositions and methods for detection of Candida species
US9803237B2 (en) 2012-04-24 2017-10-31 California Institute Of Technology Slip-induced compartmentalization
EP2664914A1 (en) 2012-05-16 2013-11-20 Koninklijke Philips N.V. Magnetically assisted processing of a medium
US10289800B2 (en) 2012-05-21 2019-05-14 Ariosa Diagnostics, Inc. Processes for calculating phased fetal genomic sequences
EP2861787B1 (en) 2012-06-18 2017-09-20 Nugen Technologies, Inc. Compositions and methods for negative selection of non-desired nucleic acid sequences
DE102012012523B4 (en) * 2012-06-26 2015-02-12 Magnamedics Gmbh Purification of nucleic acids
US20150011396A1 (en) 2012-07-09 2015-01-08 Benjamin G. Schroeder Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing
CN104812947B (en) 2012-07-17 2018-04-27 考希尔股份有限公司 The system and method for detecting hereditary variation
US9092401B2 (en) 2012-10-31 2015-07-28 Counsyl, Inc. System and methods for detecting genetic variation
EP2875131B1 (en) 2012-07-18 2018-03-14 Siemens Healthcare Diagnostics Inc. A method of normalizing biological samples
EP2875156A4 (en) 2012-07-19 2016-02-24 Ariosa Diagnostics Inc Multiplexed sequential ligation-based detection of genetic variants
US9903001B1 (en) 2012-07-19 2018-02-27 National Technology & Engineering Solutions Of Sandia, Llc Quantitative detection of pathogens in centrifugal microfluidic disks
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
MX364957B (en) 2012-08-14 2019-05-15 10X Genomics Inc Microcapsule compositions and methods.
US9422602B2 (en) 2012-08-15 2016-08-23 Bio-Rad Laboratories, Inc. Methods and compositions for determining nucleic acid degradation
JP6608280B2 (en) 2012-09-25 2019-11-20 キアゲン ゲーエムベーハー Biological sample stabilization
US10364455B2 (en) 2012-09-27 2019-07-30 Bioo Scientific Corporation Methods and compositions for improving removal of ribosomal RNA from biological samples
JP1628115S (en) 2012-10-24 2019-04-01
US20140322706A1 (en) 2012-10-24 2014-10-30 Jon Faiz Kayyem Integrated multipelx target analysis
AR093878A1 (en) * 2012-12-10 2015-06-24 Agrigenetics Inc RECOVERY OF GENOMIC DNA FROM SAMPLES OF REMOVED REMOVED SEEDS
EP2931661B1 (en) 2012-12-11 2017-11-08 Qiagen GmbH Preparation of silica particles
CA2894694C (en) 2012-12-14 2023-04-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2014118166A1 (en) * 2013-01-31 2014-08-07 Ge Healthcare Uk Limited Improvements in and relating to the transfer and storage of biological material
US9411930B2 (en) 2013-02-01 2016-08-09 The Regents Of The University Of California Methods for genome assembly and haplotype phasing
GB2519255B (en) 2013-02-01 2016-01-06 Univ California Methods for genome assembly and haplotype phasing
US9304128B1 (en) 2013-02-01 2016-04-05 Sandia Corporation Toxin activity assays, devices, methods and systems therefor
US9493766B2 (en) 2013-02-04 2016-11-15 Corning Incorporated PCR reaction cleanup buffers
US10745686B2 (en) 2013-02-08 2020-08-18 Qiagen Gmbh Method for separating DNA by size
BR112015019159A2 (en) 2013-02-08 2017-07-18 10X Genomics Inc polynucleotide barcode generation
WO2014160233A1 (en) * 2013-03-13 2014-10-02 Abbott Molecular Inc. Systems and methods for isolating nucleic acids
AU2013202805B2 (en) 2013-03-14 2015-07-16 Gen-Probe Incorporated System and method for extending the capabilities of a diagnostic analyzer
WO2014144092A1 (en) 2013-03-15 2014-09-18 Nugen Technologies, Inc. Sequential sequencing
EP3520895A1 (en) 2013-03-15 2019-08-07 Genmark Diagnostics Inc. Fluid container with cantilevered lance
CN105283550A (en) 2013-03-18 2016-01-27 凯杰有限公司 Stabilisation of biological samples
CN105164258B (en) 2013-03-18 2021-05-18 凯杰有限公司 Stabilization and isolation of extracellular nucleic acids
SG11201600550WA (en) 2013-07-25 2016-02-26 Dch Molecular Diagnostics Inc Methods and compositions for detecting bacterial contamination
USD881409S1 (en) 2013-10-24 2020-04-14 Genmark Diagnostics, Inc. Biochip cartridge
US9498778B2 (en) 2014-11-11 2016-11-22 Genmark Diagnostics, Inc. Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system
US10415083B2 (en) * 2013-10-28 2019-09-17 The Translational Genomics Research Institute Long insert-based whole genome sequencing
US9486756B2 (en) 2013-11-08 2016-11-08 Covaris, Inc. Method and apparatus for shearing of genomic material using acoustic processing
CA2929596C (en) 2013-11-13 2022-07-05 Nugen Technologies, Inc. Compositions and methods for identification of a duplicate sequencing read
EP3071333A4 (en) 2013-11-18 2017-11-15 IntegenX Inc. Cartridges and instruments for sample analysis
US9803238B1 (en) 2013-11-26 2017-10-31 National Technology & Engineering Solutions Of Sandia, Llc Method and apparatus for purifying nucleic acids and performing polymerase chain reaction assays using an immiscible fluid
EP3077072B1 (en) 2013-12-02 2019-03-06 Biocartis N.V. Extraction of circulating nucleic acids
US11859246B2 (en) 2013-12-11 2024-01-02 Accuragen Holdings Limited Methods and compositions for enrichment of amplification products
US11286519B2 (en) 2013-12-11 2022-03-29 Accuragen Holdings Limited Methods and compositions for enrichment of amplification products
WO2015089243A1 (en) 2013-12-11 2015-06-18 The Regents For Of The University Of California Methods for labeling dna fragments to recontruct physical linkage and phase
AU2014362227B2 (en) 2013-12-11 2021-05-13 Accuragen Holdings Limited Compositions and methods for detecting rare sequence variants
US20150167065A1 (en) * 2013-12-13 2015-06-18 General Electric Company Isothermal amplification of nucleic acids within a porous matrix
WO2015131107A1 (en) 2014-02-28 2015-09-03 Nugen Technologies, Inc. Reduced representation bisulfite sequencing with diversity adaptors
EP3119197A1 (en) 2014-03-18 2017-01-25 Qiagen GmbH Stabilization and isolation of extracellular nucleic acids
EP2921556A1 (en) 2014-03-21 2015-09-23 Lexogen GmbH Copy number preserving RNA analysis method
CN114534806B (en) 2014-04-10 2024-03-29 10X基因组学有限公司 Fluidic devices, systems and methods for packaging and partitioning reagents and uses thereof
WO2015179098A1 (en) 2014-05-21 2015-11-26 Integenx Inc. Fluidic cartridge with valve mechanism
WO2015200893A2 (en) 2014-06-26 2015-12-30 10X Genomics, Inc. Methods of analyzing nucleic acids from individual cells or cell populations
WO2016019360A1 (en) 2014-08-01 2016-02-04 Dovetail Genomics Llc Tagging nucleic acids for sequence assembly
EP3552690A1 (en) 2014-10-22 2019-10-16 IntegenX Inc. Systems and methods for sample preparation, processing and analysis
WO2016065218A1 (en) 2014-10-23 2016-04-28 Corning Incorporated Polymer-encapsulated magnetic nanoparticles
CN107002128A (en) 2014-10-29 2017-08-01 10X 基因组学有限公司 The method and composition being sequenced for target nucleic acid
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
AU2015342907A1 (en) * 2014-11-07 2017-05-25 The Johns Hopkins University Chaotrope- and volatile-free method for purifying nucleic acids from plasma
US9598722B2 (en) 2014-11-11 2017-03-21 Genmark Diagnostics, Inc. Cartridge for performing assays in a closed sample preparation and reaction system
WO2016075701A2 (en) * 2014-11-11 2016-05-19 Scigenom Labs Pvt. Ltd. A method for extraction of dna using naked magnetic nanoparticles
US10005080B2 (en) 2014-11-11 2018-06-26 Genmark Diagnostics, Inc. Instrument and cartridge for performing assays in a closed sample preparation and reaction system employing electrowetting fluid manipulation
US9702871B1 (en) 2014-11-18 2017-07-11 National Technology & Engineering Solutions Of Sandia, Llc System and method for detecting components of a mixture including a valving scheme for competition assays
SG11201705615UA (en) 2015-01-12 2017-08-30 10X Genomics Inc Processes and systems for preparing nucleic acid sequencing libraries and libraries prepared using same
EP3259696A1 (en) 2015-02-17 2017-12-27 Dovetail Genomics LLC Nucleic acid sequence assembly
US10697000B2 (en) * 2015-02-24 2020-06-30 10X Genomics, Inc. Partition processing methods and systems
CA2975958A1 (en) 2015-02-24 2016-09-01 10X Genomics, Inc. Methods for targeted nucleic acid sequence coverage
US10254298B1 (en) 2015-03-25 2019-04-09 National Technology & Engineering Solutions Of Sandia, Llc Detection of metabolites for controlled substances
US11807896B2 (en) 2015-03-26 2023-11-07 Dovetail Genomics, Llc Physical linkage preservation in DNA storage
EP3303630B1 (en) 2015-06-05 2022-01-05 Qiagen GmbH Method for separating dna by size
WO2017041013A1 (en) 2015-09-04 2017-03-09 Mo Bio Laboratories, Inc. Small-molecule mediated size selection of nucleic acids
EP3344643A4 (en) 2015-09-04 2019-05-01 Qiagen Sciences LLC Methods for co-isolation of nucelic acids and proteins
WO2017042819A1 (en) 2015-09-11 2017-03-16 Molecular Detection Israel Ltd. Methods for isolating microbial cells from a blood sample
AU2016334233B2 (en) 2015-10-09 2023-01-05 Accuragen Holdings Limited Methods and compositions for enrichment of amplification products
CN108368542B (en) 2015-10-19 2022-04-08 多弗泰尔基因组学有限责任公司 Methods for genome assembly, haplotype phasing, and target-independent nucleic acid detection
EP3368668B1 (en) 2015-10-28 2023-11-29 Silicon Valley Scientific, Inc. Method and apparatus for encoding cellular spatial position information
CN108291250B (en) 2015-11-20 2022-05-27 凯杰有限公司 Method for preparing sterilized composition for stabilizing extracellular nucleic acid
CN115927547A (en) 2015-12-03 2023-04-07 安可济控股有限公司 Methods and compositions for forming ligation products
EP4144861A1 (en) 2015-12-04 2023-03-08 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
CA3011901A1 (en) 2016-01-21 2017-07-27 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of bacteria
JP7441003B2 (en) 2016-02-23 2024-02-29 ダブテイル ゲノミクス エルエルシー Generation of phased read sets and haplotype phasing for genome assembly
EP3954771A1 (en) 2016-05-13 2022-02-16 Dovetail Genomics, LLC Recovering long-range linkage information from preserved samples
WO2017197338A1 (en) 2016-05-13 2017-11-16 10X Genomics, Inc. Microfluidic systems and methods of use
US11427866B2 (en) 2016-05-16 2022-08-30 Accuragen Holdings Limited Method of improved sequencing by strand identification
US10774393B2 (en) 2016-05-20 2020-09-15 Roche Molecular Systems, Inc. Cell surface marker depletion in a sample processing device
WO2017218777A1 (en) 2016-06-17 2017-12-21 California Institute Of Technology Nucleic acid reactions and related methods and compositions
WO2018005811A1 (en) 2016-06-30 2018-01-04 Grail, Inc. Differential tagging of rna for preparation of a cell-free dna/rna sequencing library
GB2551801A (en) * 2016-06-30 2018-01-03 Lgc Genomics Ltd Methods
WO2018023033A1 (en) 2016-07-29 2018-02-01 Western Michigan University Research Foundation Magnetic nanoparticle-based gyroscopic sensor
US10981174B1 (en) 2016-08-04 2021-04-20 National Technology & Engineering Solutions Of Sandia, Llc Protein and nucleic acid detection for microfluidic devices
US10406528B1 (en) 2016-08-04 2019-09-10 National Technology & Engineering Solutions Of Sandia, Llc Non-contact temperature control system for microfluidic devices
JP6966052B2 (en) 2016-08-15 2021-11-10 アキュラーゲン ホールディングス リミテッド Compositions and Methods for Detecting Rare Sequence Variants
US10786811B1 (en) 2016-10-24 2020-09-29 National Technology & Engineering Solutions Of Sandia, Llc Detection of active and latent infections with microfluidic devices and systems thereof
DE102016121483B4 (en) * 2016-11-09 2020-06-18 Axagarius Gmbh & Co. Kg Particulate solid composite material for nucleic acid purification, containing magnetic nanoparticles, process for its production and its use
US11231347B2 (en) 2016-11-29 2022-01-25 S2 Genomics, Inc. Method and apparatus for processing tissue samples
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2018140966A1 (en) 2017-01-30 2018-08-02 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
WO2018140452A1 (en) 2017-01-30 2018-08-02 Counsyl, Inc. Enrichment of cell-free dna from a biological sample
EP3612646A1 (en) 2017-04-18 2020-02-26 Dovetail Genomics, LLC Nucleic acid characteristics as guides for sequence assembly
WO2018199689A2 (en) * 2017-04-28 2018-11-01 주식회사 이지다이아텍 Automated immunoassay device and method using large magnetic particle complex
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
US20190093155A1 (en) 2017-05-25 2019-03-28 Roche Molecular Systems, Inc. Multiplex Nucleic Acid Amplification Assay
EP4230746A3 (en) 2017-05-26 2023-11-01 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10844372B2 (en) 2017-05-26 2020-11-24 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11384351B2 (en) 2017-07-27 2022-07-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and tools for purifying nucleic acids and using polymerized tubulin
WO2019060722A2 (en) 2017-09-22 2019-03-28 X Gen Us Co. Methods and compositions for preparing polynucleotides
US11099202B2 (en) 2017-10-20 2021-08-24 Tecan Genomics, Inc. Reagent delivery system
SG11201913654QA (en) 2017-11-15 2020-01-30 10X Genomics Inc Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
WO2019106568A1 (en) 2017-11-29 2019-06-06 Basf Se Plants having increased tolerance to herbicides
CA3090102A1 (en) 2018-01-31 2019-08-08 Dovetail Genomics, Llc Sample prep for dna linkage recovery
US11203782B2 (en) 2018-03-29 2021-12-21 Accuragen Holdings Limited Compositions and methods comprising asymmetric barcoding
CN112262218A (en) 2018-04-06 2021-01-22 10X基因组学有限公司 System and method for quality control in single cell processing
CN113383083A (en) 2018-04-27 2021-09-10 埃克斯基因美国公司 Methods and compositions for preparing polynucleotides
WO2019232504A2 (en) 2018-06-01 2019-12-05 S2 Genomics, Inc. Method and apparatus for processing tissue samples
EP3824484A1 (en) 2018-07-19 2021-05-26 Beckman Coulter Inc. Magnetic particles
US11515012B1 (en) 2018-09-22 2022-11-29 Mark Gordon Arnold Method and apparatus for a pipelined DNA memory hierarchy
WO2020069385A1 (en) 2018-09-28 2020-04-02 Beckman Coulter, Inc. Isolation of dna and rna from a single sample
EP3905881A1 (en) 2019-01-04 2021-11-10 QIAGEN GmbH Urine stabilization
US11807909B1 (en) 2019-09-12 2023-11-07 Zymo Research Corporation Methods for species-level resolution of microorganisms
US11857981B2 (en) 2019-12-23 2024-01-02 10X Genomics, Inc. Magnetic separator for an automated single cell sequencing system
CA3131632A1 (en) 2019-12-04 2021-06-10 Tong Liu Preparation of dna sequencing libraries for detection of dna pathogens in plasma
CN115104033A (en) 2019-12-23 2022-09-23 贝克曼库尔特有限公司 Method for transferring liquid from reagent reservoir using mechanical processor
EP4126374A1 (en) 2020-04-03 2023-02-08 Beckman Coulter Inc. Electromagnetic assemblies for processing fluids
US11701668B1 (en) 2020-05-08 2023-07-18 10X Genomics, Inc. Methods and devices for magnetic separation
US11946038B1 (en) 2020-05-29 2024-04-02 10X Genomics, Inc. Methods and systems including flow and magnetic modules
CN116601308A (en) 2020-12-22 2023-08-15 豪夫迈·罗氏有限公司 Method for multiplex real-time PCR using large Stokes shift fluorescent dyes
CN112501161B (en) * 2020-12-23 2023-03-28 华南师范大学 Double-magnetic-particle-intervention DNA extraction and purification method
GB2603968A (en) 2021-02-23 2022-08-24 Imperial College Innovations Ltd Lid assembly for a sample tube, method of using the same to collect magnetic beads, and sample processing kit
WO2022183205A1 (en) 2021-02-25 2022-09-01 Beckman Coulter, Inc. Rapidly-sedimenting magnetic particles and applications thereof
WO2023031161A1 (en) 2021-09-03 2023-03-09 BASF Agricultural Solutions Seed US LLC Plants having increased tolerance to herbicides
CN113881644A (en) * 2021-09-28 2022-01-04 江苏金迪克生物技术股份有限公司 Method for removing host DNA in rabies vaccine
WO2023131803A1 (en) 2022-01-10 2023-07-13 Imperial College Innovations Limited Lyophilised nucleic acid amplification reaction composition
GB2620799A (en) 2022-07-22 2024-01-24 Life Tech As Particles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025709A1 (en) * 1992-06-09 1993-12-23 Medical Research Council Preparation of nucleic acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628037A (en) * 1983-05-12 1986-12-09 Advanced Magnetics, Inc. Binding assays employing magnetic particles
US4698302A (en) * 1983-05-12 1987-10-06 Advanced Magnetics, Inc. Enzymatic reactions using magnetic particles
US4695393A (en) * 1983-05-12 1987-09-22 Advanced Magnetics Inc. Magnetic particles for use in separations
US4672040A (en) * 1983-05-12 1987-06-09 Advanced Magnetics, Inc. Magnetic particles for use in separations
US4554088A (en) * 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
GB9003253D0 (en) * 1990-02-13 1990-04-11 Amersham Int Plc Precipitating polymers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025709A1 (en) * 1992-06-09 1993-12-23 Medical Research Council Preparation of nucleic acids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAWKINS, TREVOR L. ET AL: "DNA purification and isolation using a solid-phase", NUCLEIC ACIDS RES. (1994), 22(21), 4543-4 CODEN: NARHAD;ISSN: 0305-1048 *
HAWKINS, TREVOR: "M13 single-strand purification using a biotinylated probe and streptavidin coated magnetic beads", DNA SEQUENCE (1992), 3(2), 65-9 CODEN: DNSEES;ISSN: 1042-5179 *

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119194B2 (en) 1995-07-07 2006-10-10 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
EP0885958A4 (en) * 1996-02-25 2002-05-22 Prec System Science Co Ltd Method for treating biopolymers, microorganisms or materials by using more than one type of magnetic particles
EP0885958A1 (en) * 1996-02-25 1998-12-23 Precision System Science Co., Ltd. Method for treating biopolymers, microorganisms or materials by using more than one type of magnetic particles
WO1999058664A1 (en) * 1998-05-14 1999-11-18 Whitehead Institute For Biomedical Research Solid phase technique for selectively isolating nucleic acids
US6534262B1 (en) 1998-05-14 2003-03-18 Whitehead Institute For Biomedical Research Solid phase technique for selectively isolating nucleic acids
US6433160B1 (en) 1998-10-30 2002-08-13 Becton, Dickinson And Company Method for purification and manipulation of nucleic acids using paramagnetic particles
EP1674571A3 (en) * 1998-10-30 2008-08-13 Becton, Dickinson and Company Use of paramagnetic material in the purification and manipulation of nucleic acids
EP1002860A1 (en) * 1998-10-30 2000-05-24 Becton Dickinson and Company Method for purification and manipulation of nucleic acids using paramagnetic particles
WO2001040459A2 (en) * 1999-12-03 2001-06-07 InViTek Gesellschaft für Biotechnik & Biodesign mbH Surface modified supporting materials for binding biological materials, method for the production and use thereof
WO2001040459A3 (en) * 1999-12-03 2001-12-27 Invitek Biotechnik & Biodesign Surface modified supporting materials for binding biological materials, method for the production and use thereof
US6936414B2 (en) 1999-12-22 2005-08-30 Abbott Laboratories Nucleic acid isolation method and kit
WO2001046404A1 (en) * 1999-12-22 2001-06-28 Abbott Laboratories Nucleic acid isolation method and kit
WO2001059098A2 (en) * 2000-02-11 2001-08-16 Eppendorf Ag Method for purifying nucleic acids
WO2001059098A3 (en) * 2000-02-11 2002-05-23 Eppendorf Ag Method for purifying nucleic acids
US7081192B1 (en) * 2000-08-08 2006-07-25 Aviva Biosciences Corporation Methods for manipulating moieties in microfluidic systems
EP2363476A1 (en) * 2001-02-16 2011-09-07 Promega Corporation Magnetic isolation and purification of nucleic acids
EP1368629A4 (en) * 2001-02-16 2005-07-06 Cortex Biochem Inc Magnetic isolation and purification of nucleic acids
EP1368629A1 (en) * 2001-02-16 2003-12-10 Cortex Biochem Inc. Magnetic isolation and purification of nucleic acids
EP2090655A1 (en) * 2001-02-16 2009-08-19 Promega Corporation Magnetic isolation and purification of nucleic acids
US7264927B2 (en) 2001-11-06 2007-09-04 Cortex Biochem, Inc. Isolation and purification of nucleic acids
EP2000533A3 (en) * 2001-11-06 2009-07-08 Promega Corporation Isolation and purification of nucleic acids
EP2258845A3 (en) * 2001-11-06 2012-03-21 Promega Corporation Isolation and purification of nucleic acids
EP1442045A2 (en) * 2001-11-06 2004-08-04 Cortex Biochem Inc. Isolation and purification of nucleic acids
WO2003040687A2 (en) 2001-11-06 2003-05-15 Cortex Biochem, Inc. Isolation and purification of nucleic acids
EP1442045A4 (en) * 2001-11-06 2006-09-27 Cortex Biochem Inc Isolation and purification of nucleic acids
US8026068B2 (en) 2002-01-08 2011-09-27 Roche Molecular Systems, Inc. Use of silica material in an amplification reaction
WO2005089929A3 (en) * 2004-03-18 2005-11-24 Ambion Inc Modified surfaces as solid supports for nucleic acid purification
EP2292789A1 (en) * 2004-03-18 2011-03-09 Ambion, Inc. Modified surfaces as solid supports for nucleic acid purification
WO2005089929A2 (en) 2004-03-18 2005-09-29 Ambion , Inc. Modified surfaces as solid supports for nucleic acid purification
US9464315B2 (en) 2004-03-18 2016-10-11 Applied Biosystems, Llc Modified surfaces as solid supports for nucleic acid purification
US8426126B2 (en) 2004-03-18 2013-04-23 Applied Biosystems, Llc Modified surfaces as solid supports for nucleic acid purification
US7527929B2 (en) 2004-07-30 2009-05-05 Agencourt Bioscience Corporation Methods of isolating nucleic acids using multifunctional group-coated solid phase carriers
EP1799846A2 (en) * 2004-09-16 2007-06-27 Lumigen, Inc. Methods for isolating nucleic acids from biological and cellular materials
EP1799847A2 (en) * 2004-09-16 2007-06-27 Lumigen, Inc. Simplified methods for isolating nucleic acids from cellular materials
EP1799846A4 (en) * 2004-09-16 2008-01-16 Nexgen Diagnostics Llc Methods for isolating nucleic acids from biological and cellular materials
EP1799847A4 (en) * 2004-09-16 2007-12-12 Nexgen Diagnostics Llc Simplified methods for isolating nucleic acids from cellular materials
DE102007009347A1 (en) 2007-02-27 2008-08-28 Agowa Gmbh Isolating nucleic acids comprises binding the nucleic acids adsorbtive to polar surfaces, washing the surfaces with substances solution after removing the binding mixture, which have an affinity to polar surfaces and to the nuclei acids
WO2009070465A1 (en) * 2007-11-29 2009-06-04 New England Biolabs, Inc. Selective purification of small rnas from mixtures
GB2455780A (en) * 2007-12-21 2009-06-24 Zainulabedin Mohamedali Saiyed Nucleic acid separation
EP2157181A1 (en) 2008-08-13 2010-02-24 AGOWA Gesellschaft für molekularbiologische Technologie mbH Method for isolating nucleic acids and test kit
WO2012069660A1 (en) * 2010-11-26 2012-05-31 Invitrogen Dynal As Use of polyols in nucleic acid processing
US11261480B2 (en) 2010-11-26 2022-03-01 Life Technologies As Nucleic acid preparation method
EP2993232A1 (en) * 2010-11-26 2016-03-09 Life Technologies AS Nucleic acid preparation method
EP3409777A1 (en) * 2010-11-26 2018-12-05 Life Technologies AS Nucleic acid preparation method
US9909165B2 (en) 2010-11-26 2018-03-06 Life Technologies Corporation Nucleic acid preparation method
US9708645B2 (en) 2010-11-26 2017-07-18 Life Technologies Corporation Nucleic acid preparation method
EP2969140A4 (en) * 2013-03-15 2017-05-03 Abbott Molecular Inc. One-step procedure for the purification of nucleic acids
US9803230B2 (en) 2013-03-15 2017-10-31 Abbott Molecular Inc. One-step procedure for the purification of nucleic acids
EP3828284A1 (en) * 2013-03-15 2021-06-02 Abbott Molecular Inc. One-step procedure for the purification of nucleic acids
EP2969140A1 (en) * 2013-03-15 2016-01-20 Abbott Molecular Inc. One-step procedure for the purification of nucleic acids
WO2016077294A1 (en) * 2014-11-14 2016-05-19 Corning Incorporated Methods and kits for post-ivt rna purification
WO2016079509A1 (en) * 2014-11-18 2016-05-26 Cambridge Epigenetix Limited Methods for nucleic acid isolation
EP3061823A1 (en) * 2015-02-25 2016-08-31 QIAGEN GmbH Method for extracting nucleic acids from an agarose matrix
EP3141298A1 (en) 2015-09-09 2017-03-15 National Center For Scientific Research "Demokritos" Polymeric microfluidic device for nucleic acid purification fabricated via plasma micro-nanotexturing
US10344274B2 (en) 2016-02-16 2019-07-09 Life Magnetics, Inc. Methods for separating nucleic acids with graphene coated magnetic beads
WO2018109075A1 (en) * 2016-12-15 2018-06-21 Qiagen Gmbh Method for isolating highly pure nucleic acid with magnetic particles
WO2020260620A1 (en) * 2019-06-28 2020-12-30 Qiagen Gmbh Method for enriching nucleic acids by size
WO2020260618A1 (en) * 2019-06-28 2020-12-30 Qiagen Gmbh Method for separating nucleic acid molecules by size
WO2021122846A1 (en) * 2019-12-16 2021-06-24 Qiagen Gmbh Enrichment method

Also Published As

Publication number Publication date
US5705628A (en) 1998-01-06
US5898071A (en) 1999-04-27
IL115352A0 (en) 1995-12-31
IL115352A (en) 2009-02-11

Similar Documents

Publication Publication Date Title
US5705628A (en) DNA purification and isolation using magnetic particles
JP4369619B2 (en) Rapid and simple isolation method for circular nucleic acids
US6534262B1 (en) Solid phase technique for selectively isolating nucleic acids
US20060078923A1 (en) Method for isolating nucleic acids
EP0508985B1 (en) Method and kit for purifying nucleic acids
US7560228B2 (en) Solid-phase nucleic acid isolation
US20020106686A1 (en) Methods and reagents for the isolation of nucleic acids
US20070054285A1 (en) Method for isolating nucleic acids
JP2002531126A (en) Formulations and methods for isolation of nucleic acids from any complex starting material and subsequent complex gene analysis
EP0792355A1 (en) Method for purifying nucleic acids from homogeneous mixtures
US20060160085A1 (en) Novel buffer formulations for isolating purifying and recovering long-chain and short-chain nucleic acids
US20090306359A1 (en) Non-alcoholic buffer formulations for isolating, purifying and recovering long-chain and short-chain nucleic acids
ENGELSTEIN et al. An efficient, automatable template preparation for high throughput sequencing
CA2315257A1 (en) Method for isolating short and long-chain nucleic acids
JP3811767B6 (en) Method for purifying nucleic acids from a homogeneous mixture

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase